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Abstract
Background: Despite the advantages of living donor kidney transplantation (LDKT), there are
barriers that potential donors face that make living donation less appealing. Research supports
the use of telehealth as an effective method of enhancing access to care and building efficiencies.
Aims/Objectives: To evaluate access to care, effectiveness, financial impact, and experience after
implementing telehealth as a means of communicating with living donors.
Methods: Utilizing a pretest-posttest design, an analysis was performed among medically cleared
donors evaluated in-person between January 1, 2019 to December 31, 2019 (Control Group;
N=64) and donors evaluated via telehealth (Zoom®) between January 1, 2021 to December 31,
2021 (Intervention Group; N=64). Mean outcome measures included referral date to evaluation
date (access to care); evaluation date to medical clearance date (effectiveness); and estimated
out-of-pocket costs related to travel and lost wages (financial impact). Telehealth Usability
Questionnaires (TUQ) were used to evaluate healthcare provider/patient experience.
Results: Retrospective analysis of 128 randomly selected donors showed that compared to inperson evaluations, telehealth donors were scheduled for an evaluation faster (51.67 days [SD:
18.92] vs 30.45 days [SD:14.29]; p<0.001); telehealth evaluations did not cause a significant
delay in the time it took to clear donors for surgery; and out-of-pocket expenses for telehealth
donors was significantly lower ($1029 [SD: $1331] vs $1875 [SD: $2022]; p=.006). In addition,
TUQ scores from patients (N=64) and healthcare providers (N=12) revealed a high satisfaction
rate with telehealth (Zoom®).
Conclusion: The use of telehealth may improve access to care and alleviate the financial impact,
making living donor evaluations more accessible and convenient for some interested individuals.
Nevertheless, there is no best practice guidance available for living donor evaluations via
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telehealth. Collaborative efforts are needed to advance regulatory policies and ongoing
assessment is needed to ensure telehealth remains a safe and effective option for evaluating
donors.
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Evaluating Telehealth as a Means of Communicating with Living Donors and its Effects on
Quality of Care
This quality improvement study took place at a highly recognized university hospital and
transplant center located in Washington D.C. specializing in adult kidney transplantation (≥ 18
years of age) and living kidney donation. As a nationally ranked Center of Excellence, our
organization plays an active role in overcoming the barriers to transplantation. Kidney
transplantation is the preferred treatment for end stage renal disease (ESRD) patients and is
associated with increased quality of life and reduced morbidity and mortality compared with
dialysis (Neipp et al., 2006). Despite strong evidence for improved quality of life and survival
after transplantation, there is a large gap between the number of patients who need a kidney
transplant and the number of available organs (Kucirka et al., 2012). As the national deceased
donor waitlist continues to grow, the transplant community has supported living kidney donation
as an advantageous solution to solving the organ shortage crisis, and additionally, has recognized
the notable advantages a living donor kidney transplant (LDKT) offers recipients compared to a
deceased donor transplant. Telemedicine practice has surged dramatically across transplant
centers in the U.S. because of the COVID-19 pandemic in efforts to sustain access to kidney
transplantation and maintain continuity of care with heightened public health consciousness.
Telemedicine has allowed our transplant center to connect safely with our donors to ensure
contact was uninterrupted, but it has also highlighted the positive impact Telehealth can have on
addressing donor-reported barriers in access to kidney donation. Nonetheless, prospective
evaluation is needed to determine whether reliance on telehealth for communication with donors
affects quality of care including access to care, effectiveness, financial impact, and experience.

EVALUATING TELEHEALTH FOR LIVING DONORS

8

Background and Significance
Per the Organ Procurement and Transplant Network (OPTN), there were almost 95,000
men, women, and children registered on the national transplant waitlist for a kidney transplant in
2019, but there were only 23,401 kidney transplants performed (16,004 transplants from
deceased donors, and 7,397 transplants from living donors) (OPTN, 2020). Depending on what
region of the country a patient lives, the average wait time for a deceased donor kidney
transplant can be between 5 to 7 years (Saran et. al., 2017). The advantages of a living donor
kidney transplant versus deceased donor transplantation are significant allowing for earlier
transplantation and the greatest long-term survival (Garrick, 2007). Despite this, there are several
barriers that potential living donors face that make living donation less appealing. Many donors
incur out-of-pocket costs during evaluation, surgery, and recovery, including costs for travel,
accommodation, and time off work, resulting in financial loss. Evidence across multiple studies
demonstrate that up to 96% of donors have reported out-of-pocket costs with a range of $2,000$8,000 (Tietjen et al., 2019). The transplant community continues to look for ways to improve
living donor evaluation programs and advocate for the enactment of federally implemented
living donation policies, which would decrease the financial obstacles that discourage individuals
from donating and would significantly help address the organ shortage crisis.
Living Donor Evaluation Process (In-person vs Telehealth)
In-person Evaluations
Prior to March 2020 before the pandemic, in-person evaluations were the standard of care
and the only option available at our transplant center. Regardless of distance from Washington
D.C., potential donors were scheduled for a Full-Day (~7:00 AM to 4:30 PM) in-person living
donor evaluation including a fasting lab appointment, donor education class, one-on-one

EVALUATING TELEHEALTH FOR LIVING DONORS

9

consults, EKG/Stress Echo, Abdominal CTA, and a Chest X-ray. In-person living kidney donor
evaluations took place twice weekly, on Wednesdays and Fridays. A max of 5 potential donors
were scheduled for each session. If a donor was medically cleared, they would also be scheduled
for an in-person pre-surgical consult/lab appointment 7-10 days prior to their scheduled surgery
date. Furthermore, all donors are required to complete federally mandated follow-up visits at 1week, 6-months, 1-year, and-2 years post donation. These follow-up requirements were also only
scheduled as in-person appointments and resulted in most donors making at least four additional
trips to the transplant center after their kidney donation surgery.
Telehealth Evaluations
After March 2020, to mitigate infection and spread of COVID-19, we transitioned inperson appointments to telehealth visits through the virtual platform, Zoom®. Potential donors
are now scheduled for a two-part evaluation, planned consecutively on two separate days: (Part1) a telehealth evaluation to complete donor education class and one-on-one consults with the
living donor team (~8:30AM to 12:00PM), and (Part-2) a testing day at our hospital including
fasting labs, EKG/Stress Echo, Abdominal CTA, and Chest X-ray (~8:00 M to 12:00PM). If the
potential donor lives out-of-state, labs are completed at a Quest Diagnostics facility and
diagnostic testing can be set up at a National Kidney Registry-affiliated transplant center close to
where the potential donor lives, if there is a center near them. (The NKR is a nation-wide
organization dedicated to increasing the number of kidney transplants from living donors and
improving donor-recipient matches. There are 80+ transplant centers across the U.S. affiliated
with the NKR helping to facilitate kidney transplants.) Telehealth living donor evaluations take
place twice weekly, on Wednesdays and Fridays. On average, 5-6 potential donors can be booked
for each session, but we frequently accommodate more because our evaluation capacity is not
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affected by the amount of space available in the transplant clinic, which was often experienced
with in-person evaluations. If a donor is medically cleared, they are also scheduled for an inperson pre-surgical consult/lab appointment 7-10 days prior to their scheduled surgery date at our
hospital. Federally mandated donor follow-up visits at 1-week, 6-months, 1-year, and-2 years
post donation are now being done though Telehealth as well.
Needs Assessment
A SWOT Analysis was performed to identify organizational barriers and facilitators to
successfully implement this quality improvement initiative. This activity is important to identify
what the organization does well, and where improvements are needed to ensure the
organization’s success going forward. Living donation practice carries additional responsibilities
for transplantation programs, given the potential risks to healthy donors undergoing a surgical
procedure for the benefit of another person, and the risks of disease transmission to an
immunosuppressed recipient. Efforts to develop, update, and follow best practices must be
consistent to make sure living donor evaluations and LDKTs remain as safe as possible, and
serve and support the best outcomes of donors and their recipients. To ensure the increased
utilization of telehealth observed during the COVID-19 pandemic is not squandered, lessons
from this period of deregulation need to be thoughtfully extracted. Some modifications, such as
waiving components of HIPAA, were clearly intended for a crisis but can suggest areas in which
sustained regulatory change could be beneficial. [See Appendix A: SWOT Analysis]
Facilitators
Our transplant program consists of a multidisciplinary team of nationally recognized
surgeons and medical specialists as well as transplant coordinators, social workers, and dieticians
committed to guiding and supporting patients and their loved ones through the transplant process
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and offering patients their best chance for recovery and an improved quality of life. We are a
highly trusted transplant center in a very competitive market. Out of five transplant centers in the
Washington D.C. area with living kidney donor programs, our program consistently outperforms
its local competition. Not only that, we are one of the highest volume transplant programs in the
United States and are also a national leader in paired kidney exchange and the management of
recipient and donors who are incompatible. In 2020 alone, our organization completed 106 living
donor surgeries during the COVID-19 pandemic.
Telehealth measures have been in place at our transplant center and have been utilized as
the standard for evaluation since March 2020 (i.e., no resistance to change). Leadership and other
stakeholders have been supportive of telehealth, however further evaluation was needed to assess
the quality of care. Research shows that telehealth interventions offer an evidenced-based
approach to providing patient education, timely communication, and linking dispersed healthcare
teams. Many studies have also demonstrated that telehealth is cost-effective.
Barriers
The emergence of new telehealth-related capabilities and their integration into caredelivery systems presented exciting opportunities to enhance value-based clinical care, health
promotion, and disease prevention. However, they can also present challenges as health
professionals adapt to innovations in consumer technologies, integrate these solutions into
clinical workflow, seek evidence-based guidance for decision making, and manage the evolving
relationships between care teams and their patients. With reservations of added job
responsibilities, a possible unwillingness of health professionals and/or support staff to deliver
telemedicine services is a potential threat. Staff turnover could also be a concern as all new hires
would need to be trained on telemedicine technologies, requiring additional time and resources.
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Additionally, one of the most immediate threats is the possible reluctance of the patient
population to use telemedicine services. Many may lack access to technologies, and even among
those that have such access, there may be a lack of comfort in the use of such technologies (i.e.,
older age).
Problem Statement and Project Purpose
The COVID-19 pandemic initially had profound impacts on all aspects of transplantation,
and this impact was particularly notable for LDKTs. The pandemic was an unfortunate yet
effective catalyst to address two major telemedicine roadblocks: consumer willingness to try new
care delivery models and insurance coverage. Telemedicine allowed our transplant program to
connect safely with our donors and ensure contact was uninterrupted. In fact, during the height of
the COVID-19 pandemic, we performed more kidney transplants than any other hospital in the
U.S., and successfully safeguarded all its transplant recipients and living organ donors, from
contracting COVID-19 related to an evaluation, surgical, or hospital admission related activity.
However, analysis was needed to determine whether reliance on telehealth for communication
with donors affects quality of care. As a leading Living Donor Transplant program, it is our duty
to continue to appraise additional means of decreasing obstacles to living donation while
consistently providing the most economical and highest quality of care. To maintain momentum
for telehealth services that has resulted from the COVID-19 pandemic, the U.S. cannot revert to
pre-pandemic telehealth regulations. Neither can the U.S. simply adopt the changes because they
lack nuance to support clinicians while ensuring safety and privacy for patients. Clinicians
deserve access to a more complete body of evidence on telehealth care as they make important
decisions with, and on behalf of, their patients. Patients cannot realize the benefits of telehealth if
physicians are not incentivized to maintain telehealth practices after COVID-19. Telehealth faces
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many legal and regulatory hurdles including large variations in rules, regulations, and guidelines
for practice from state to state. This variability contributes to the confusion for providers engaged
in the practice of telehealth and quality evaluation must be built into the telehealth process. The
purpose of this study was to answer the following clinical question: Among potential living
kidney donors, what is the influence of telehealth evaluations versus in-person clinic evaluations
on quality of care including access to care, financial impact, effectiveness, and experience?
Goal, Aims, and Objectives
The goal of this study was to evaluate the impact of using telehealth as the primary means
of communicating with living donors during evaluations (and follow-up appointments) and its
effect on quality of care versus in-person evaluations. To measure quality of care in a meaningful
way, the objectives were chosen to align with national quality standards by using National
Quality Forum (NQF) metrics. The 2017 NQF report, Creating a Framework to Support
Measure Development for Telehealth, provides a measurement framework organized into four
main domains: (1) access to care, (2) financial impact/cost, (3) effectiveness, and (4) experience
(NQF, 2017). Quality of care crosses all these domains (e.g., untimely care represents poorquality care, ineffective care represents low-quality care). The NQF report focuses on telehealth
not as a new type of health care, but rather as a new method for delivering existing models of
health care. The results were used to illuminate the benefits and/or harms of continuing donor
telehealth evaluations long-term after the pandemic.
Project Objectives
1. Evaluate Access to Care: Evaluating access to care addresses whether the use of
telehealth services allows individuals to be evaluated for living kidney donation
efficiently.
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2. Evaluate Effectiveness: Evaluating effectiveness addresses the impact of telehealth on
health outcomes. For this QI project, effectiveness refers to the capability of telehealth to
successfully evaluate potential living donors and medically clear them for donation
surgery.
3. Evaluate Financial Impact: The financial impact accounts for the estimated cost
savings and benefits of telehealth such as a decrease in travel costs and less time lost at
work (e.g., lost wages) for the donor.
4. Evaluate Experience of Living Donors: The experience of telehealth represents the
usability and effect of telehealth on donors, and whether the use of telehealth results in a
level of care the living donor expects.
5. Evaluate Experience of Health Care Providers: The experience of telehealth represents
the usability and effect of telehealth on health care team members, and whether the use of
telehealth results in a level of care the health clinicians expects.
Aims
1. Aim #1: Telehealth evaluations will improve access to care by decreasing the average
timeframe (mean # of days) between the date of referral (DASH questionnaire
submission date) to the donor’s scheduled evaluation appointment, after 1 year of
telehealth implementation.
2. Aim #2: Telehealth evaluations will maintain effectiveness by producing a similar
timeframe (mean # of days) between the living donor’s evaluation appointment and the
date the living donor is deemed eligible for donation/cleared for surgery, after 1 year of
telehealth implementation. (In other words, 2-part telehealth evaluations will not cause a
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significant delay in the average time it takes to medically clear the donors for surgery,
when compared to full day in-person evaluations.)
3. Aim #3: Telehealth evaluations will improve the financial impact experienced by living
donors by decreasing the average (mean) out-of-pocket costs of travel and lost wages,
after 1 year of telehealth implementation.
4. Aim #4: Potential living donors will report an overall positive experience with telehealth
(Zoom ®) over a 10-week time-period. A “positive” experience will be presumed by a
mean average score of ≤ 5.5 per question and mean average score ≤ 5.5 in each domain of
(1) usefulness, (2) ease of use, (3) effectiveness, (4) reliability, and (5) satisfaction on a
Telehealth Usability Questionnaire (TUQ) (7-point Likert scale).
5. Aim #5: Health care providers (including Surgeons, Nephrologists, Coordinators, and
Social Workers) will report an overall positive experience with telehealth
communications on a one-time survey distributed during the month of December 2021. A
“positive” experience will be presumed by a mean average score of ≤ 5.5 per question
and mean average score ≤ 5.5 in each domain of (1) usefulness, (2) ease of use, (3)
effectiveness, (4) reliability, and (5) satisfaction on a Telehealth Usability Questionnaire
(TUQ) (7-point Likert scale).
Review of Literature
An appraisal of evidence was conducted to assess the influence of telehealth versus inperson clinic visits on access to care, financial impact, effectiveness, and experience. The George
Washington University’s librarian was consulted during the literature search to identify
appropriate databases and search terms. Studies examining telehealth were first searched and
identified from PubMed and CINAHL which were both accessed through the Himmelfarb Health
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Sciences Library website. The keywords used in searching for appropriate studies were
telehealth, telemedicine, quality of care, patient satisfaction, cost effective, access to care, and
care effectiveness. Additionally, in PubMed, the search strategy included MeSH terms to capture
all pertinent articles. The search details included: (telehealth appointment [MeSH Terms]) AND
(in-person appointment [MeSH Terms]), (telemedicine [MeSH Terms]) AND (quality of care
[MeSH Terms]), (telehealth [MeSH Terms]) AND (cost effective [MeSH Terms]), (telehealth
[MeSH Terms]) AND (patient satisfaction [MeSH Terms]), (telemedicine [MeSH Terms]) AND
(care effectiveness [MeSH Terms]). After an extensive database search was completed, a manual
cross-referencing of appropriate articles was performed to find other applicable studies which led
to exploring specific journal repositories including Wiley Online Library, JAMA Network, and
Sage Journals for additional appropriate articles.
After duplicates were removed, ten journal articles were reviewed, including seven
randomized control trials, two non-experimental, cross-sectional surveys, and one systemic
review. All studies were published within the last ten years. A synthesis of the outcomes from the
studies selected support findings from additional literature which shows a positive association
between telehealth and access to care, effectiveness, financial impact, and experience. The
studies selected showed a high level of evidence (7 out of 10 studies) and good quality ratings
indicating consistent data and strong recommendations, which can be applied to most patients in
most circumstances.
Overall, the findings from the selected studies suggest that telehealth offers tremendous
potential to transform the healthcare delivery system by overcoming geographical distance,
enhancing access to care, and building efficiencies. Regarding financial impact, Wilkinson et al.
(2019), found travel burden was decreased for home telehealth participants with a savings of
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58.2 miles per visit. Dixon et al. (2016) and Gonzalez Garcia et al. (2019) agreed that a
telehealth intervention was likely to be cost-effective. Concerning effectiveness and access to
care, Noel et al. (2020) reported that 100% of Telehealth patients found the intervention to be
valuable, 98% if given the opportunity, reported they would continue using telehealth to manage
their healthcare needs, and 94% reported the remote patient monitoring technology was useful.
Additionally, Salisbury et al. (2016) found that compared with participants who received usual
in-person care, participants who received the intervention (telehealth) reported reduced anxiety
and improved access to health support and advice. Furthermore, according to Isautier et al.
(2020), respondents perceived telehealth as moderately useful to very useful for medical
appointments. Regarding experience, Wilkinson et al. (2019) found significantly higher
satisfaction for telehealth interventions compared with usual in-person treatment. Soriano et al.
(2018) stated 100% participants would recommend the telemonitoring system to a family
member or a friend, should they need it. Additionally, 93.3% of physicians would intend to use
telemonitoring when necessary, to provide health care to their patients, and 60.0% agreed to
routinely use telemonitoring with their patients. Moreover, the findings from Press et al. (2020)
suggest that patient-directed virtual education similarly improved the percentage of participants
with correct technique compared with in-person education and Polinski et al. (2016) concluded
that between 94%-99 % reported being “very satisfied” with all telehealth attributes. [See
Appendix B: Evidence Table]
EBP Translation Model
The Iowa Model-Revised: Evidence-Based Practice to Promote Quality Care (Iowa
Model Collaborative, 2017), was selected because it is the organization’s theoretical evidencebased model of choice. The use of a singular model allows for a standardized process
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improvement across the entire organization. The Iowa Model is intuitively understandable, and it
has been used in numerous academic settings and health care organizations (Gawlinski &
Rutledge, 2008). Additionally, The Iowa Model focuses on organization and collaboration,
allowing nurses to target knowledge- and problem-focused triggers, encouraging personnel to
question current nursing practices and determine whether care can be improved by using current
research findings (Titler et al., 2001).
The Iowa Model’s conceptual framework was used to guide this study for evaluating and
infusing evidenced based research findings into patient care and includes the following steps:
identify triggering issues and/or opportunities; state the clinical question or purpose; form a
team; assemble, appraise, and synthesize body of evidence; design and pilot the practice change,
integrate and sustain the practice change, and disseminate results (Iowa Model Collaborative,
2017). [See Appendix C: The Iowa Model-Revised: Evidence-Based Practice to Promote Quality
Care Flow Diagram]
Identify Triggering Issues and/or Opportunities
Health care delivery shifted during the COVID-19 pandemic, with telehealth encounters
sharply increasing. Availability and promotion of telehealth services have played a prominent
role in increasing access to services during the public health emergency. With expanded access
and improved reimbursement policies in place, as well as ongoing acceptability by patients and
health care providers, telehealth has continued to serve as an important modality for delivering
care. The pre-pandemic, in-person donor evaluation process was not cost-effective for donors
and contributed to the donor’s concerns about financial loss which may affect their decision to
undergo evaluation, proceed with a donation, or their experience with the transplant process. In
turn, to ease the financial burden of living organ donation, especially for donors who live out of
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state, continuing telehealth practices following the pandemic may be viewed as just and ethically
responsible. For any change to take place, barriers that could hinder its progress need to be
identified. Information and skill deficit are common barriers to evidence-based practice. As
previously indicated, A SWOT analysis was performed to identify organizational barriers and
facilitators to successfully implement the quality improvement study. [See Appendix A: SWOT
Analysis]
State the Clinical Question or Purpose
Among potential living kidney donors, what is the influence of Telehealth evaluations
versus in-person clinic evaluations on quality of care including access to care, financial impact,
effectiveness, and experience?
Form a Team
A powerful guiding coalition was developed with the creation of a Project Committee
that included interested interdisciplinary stakeholders. The Project Committee was led by the
DNP student (Living Donor Transplant Coordinator), and team members included Transplant
Nephrologists, Clinical Operations Manager, the Director of Kidney Transplantation, and the
Director of Living Donation Surge. Additional multidisciplinary team members were included in
the committee to ensure all aspects of the quality improvement initiative were addressed to help
drive the change analysis effort.
Assemble, Appraise, and Synthesize the Body of Evidence
A systematic literature review and quality analysis was completed to identify, evaluate,
and summarize the findings of relevant studies regarding telehealth and quality of care. As
discussed in the literature review section, the evidence supports the effectiveness of telehealth.
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Design and Pilot the Practice Change
Designing the quality improvement study included determining inclusion/exclusion
criteria, defining project implementation and comparison groups, outcome measurements, power
analysis, and statistical analysis methods. To help combat the challenges faced when
implementing change and to increase the likelihood of success, it was essential to identify an
appropriate change model to provide a framework for maintaining the transformation. The
change theory driving this study was Kotter’s Eight Step Approach to successful organizational
change (Kotter, 1996). The eight stages Kotter identified for managers to follow to implement
successful change are: “establish a sense of urgency, create a powerful guiding coalition, develop
a vision, communicate the vision, empower others to act on the vision, plan for and create short
term wins, consolidate improvement, and produce more change, and institutionalize new
approaches (Borkowski, 2016, p. 309)”.
Integrate and Sustain the Practice Change
Since integration of telehealth to communicate with living kidney donors had already
been accomplished at our organization prior to the start of this study, prospective evaluation was
needed to determine whether reliance on telehealth affects quality of care for consideration of
permanent adoption into practice. It is critically important for interventions to utilize reliable and
valid transplant patient decision-making measures and knowledge instruments to accurately
characterize intervention effects. Evaluation is essential to seeing the value and contribution of
the evidence into practice. Evaluation will highlight the program’s impact, but its consistency
can only be assessed against an actual change occurring and having the desired effect (Pearson et
al, 2007).
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Disseminate Results
The study results have been reviewed with academic peers at George Washington
University and with leadership at our transplant organization. Telehealth practice methods will be
shared with other living donor transplant programs to promote change, including publishing
information about the study and its findings in a peer-reviewed transplant-focused journal.
Additionally, the results can be shared with other similar clinical specialties to help address any
knowledge gaps or hesitancies with implementing a telehealth evaluation program. Meanwhile,
the Project Committee will continue to evaluate the practice change at our organization on a
routine basis.
Methodology
Setting
A university hospital transplant center located in Washington D.C. specializing in adult
kidney transplantation (≥ 18 years of age) and living kidney donation.
Population
The target patient population were individuals who have expressed interest in living
kidney donation by submitting a questionnaire through the National Kidney Registry (NKR)
Donor Automated Screening & History (DASH) database (a comprehensive, online living donor
workflow platform designed to streamline the living donor intake through to post-donation
follow-up), have passed the initial screening process, and were scheduled for an evaluation to
assess safety and ability to donate a kidney in accordance with policies and standards set forth by
our transplant organization. Additionally, to measure the healthcare providers’ prospective of inperson versus telehealth evaluations, a separate target population included members of the
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healthcare team who have communicated with/evaluated donors in-person and through
telehealth.
Sample Size [N =128]
Based on level of significance (α=0.05), with 80% power, a moderate effect size (d=0.5),
and a pre-post design with different subjects, a sample of 128 living donors was selected for data
collection (64 for the control group and 64 for the intervention group).
Inclusion Criteria
Patient inclusion criteria included: (1) candidates ≥18 years old; (2) appeared for living
donor evaluation (virtually through Zoom or in-person); (3) were able to provide informed
consent; (4) completed the living donor evaluation and agreed to move forward with labs/testing;
and (5) were able to speak and understand English. Healthcare provider inclusion criteria
included: (1) those involved in the evaluation process of living donors including social workers,
transplant coordinators, nephrologists/hepatologist, surgeons, and other healthcare specialists that
are frequently required to evaluate/communicate with potential donors.
Exclusion Criteria
Exclusion criteria included: (1) significant neurocognitive disability; (2) inability to
speak, hand understand English; (3) visual impairment and inability to complete selfadministered questionnaires; (4) deemed an ineligible donor candidate at the time of evaluation
or opt-out at the time of evaluation; and (5) self-described unwillingness or inability to
participate in the research study. Healthcare Provider exclusion criteria included: (1) those not
involved in evaluating/communicating with living donors.
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Tools/Instruments
Zoom®
The virtual platform, Zoom®, is our transplant center’s telemedicine platform of choice.
Zoom® is a HIPAA compliant and secure platform that is safe, easy to use, and cost-effective. It
provides consistent high-quality video, even in low-bandwidth environments, and offers multiple
accessibility options including computer, tablet, and smart phone options.
Telehealth Usability Questionnaire (TUQ)
A Telehealth Usability Questionnaire (TUQ) was adapted to specifically measure
potential living donors’ and healthcare providers’ experience of using telehealth (Zoom®) for
evaluations and follow-up appointments. The TUQ is a 21-question survey that measures five
different components of telemedicine usability using a 7-point Likert scale with 1 indicating
strongly disagree and 7 indicating strongly agree. Measured components include usefulness, ease
of use, effectiveness, reliability, and satisfaction. The TUQ was selected because it been shown
to have independent content validity and internal consistency (Langbecker et al., 2017; Layfield
et al., 2020), it has been used in similar studies looking at telehealth in the context of Covid-19,
and because it is readily adaptable to most settings. Use of the TUQ allows for comparison with
other studies and increases generalizability of results. Although adaptation of any survey can
reduce this benefit, this option is preferred to the creation of a novel survey (Langbecker et al.,
2017), and the TUQ was intended to be modified to address varied telehealth systems (Parmanto,
Lewis, Graham, & Bertolet, 2016). [See Appendix D: TUQ Survey for Living Donor and Health
Care Professionals]
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REDCap®
The Telehealth Usability Questionnaire (TUQ) was adapted to an electronic format by
utilizing REDCap® (Research Electronic Data Capture) which is a web application for building
and managing online surveys and databases. REDCap® offers an easy-to-use and secure HIPAAcompliant method of flexible yet robust data collection, specifically geared to support online and
offline data capture for research studies and operations. Data was collected from REDCap® and
exported to password-protected Excel data spreadsheets for analysis.
Methods for Evaluating Access to Care, Effectiveness, and Financial Impact
Data was collected from retrospective chart reviews to measure and analyze telehealth
effects on donors’ access to care, effectiveness, and financial impact after a 1-year time-period.
Data was extracted from the National Kidney Registry DASH questionnaire database, OTTR
(Organ Transplant Tracking Record; transplant patient /living donor specific EMR), social
worker evaluation reports in the MedConnect EMR (Hospital/health system wide EMR), and any
other medical record documentation to help estimate donors’ travel costs, means of travel, PTO
status, days required to take off work, and lost wages.
Control Group (In-person Evaluations) [N =64]
For the control group, data was collected from a retrospective review of randomly
selected donors who completed in-person evaluations between January 1, 2019 and December
31, 2019 and were medically cleared for donation (evaluation result in OTTR = “donated” OR
evaluation phase in OTTR = “cleared for donation”). A total of 93 donors were identified that
met inclusion criteria, of which 64 subjects were randomly selected using an excel-generated
table of 64 random numbers between 1-93.
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Intervention Group (Telehealth Evaluations) [N =64]
For the intervention group, data was collected from a retrospective review of randomly
selected donors who completed telehealth evaluations between January 1, 2021 and December
31, 2021 and were medically cleared for donation (evaluation result in OTTR = “donated” OR
evaluation phase in OTTR = “cleared for donation”). A total of 85 donors were identified that
met inclusion criteria, of which 64 subjects were randomly selected using an excel-generated
table of 64 random numbers between 1-86.
Methods for Evaluating the Experience of Living Donors and Health Care Providers
As stated previously, the Telehealth Usability Questionnaire (TUQ) was adapted to
measure potential living donors’ and healthcare providers’ experience of using telehealth
(Zoom®) for living donor evaluations (and follow-up appointments).
Living Donor TUQ Survey Recruitment
Patients who completed a living donor telehealth evaluation through Zoom® between
September 29, 2021 and December 10, 2021 (10-week time-period) and met inclusion criteria
were invited to participate in the research study by completing a TUQ survey. As with most
studies of these types, we were unable to blind or mask study personnel and/or participants
regarding the study’s objectives. However, the study was unknown at the time of the potential
living donor’s virtual evaluation. At the end of the donor’s virtual visit, the Living Donor
Transplant Coordinator informed the patient of the ongoing voluntary study and provided
information for how to participate. The TUQ REDCap® survey included two parts: demographic
questions (gender, race/ethnicity, and age) and the 21-question TUQ. Data collection was
closed/completed once 64 surveys were submitted.
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Healthcare Provider TUQ Survey Recruitment
The healthcare provider telehealth survey was an adapted version of the TUQ, developed
to measure provider attitudes toward telehealth as far as integration into the practice of
evaluating living donors. To ensure anonymity, demographic questions were limited to type of
provider (social worker/independent living donor advocate, surgeon, physician, transplant
coordinator, nurse, or other). Providers with prior experience of evaluating living donors, both
through telehealth and in-person, were emailed a link to complete a one-time TUQ REDCap®
survey during the month of December 2021. Data collection was closed once all 11 eligible
health care providers submitted their survey responses.
Outcomes to be Measures
Evaluating Access to Care
Data collection methods included a retrospective chart review of control group variables
(in-person evaluations between January 1, 2019 to December 31, 2019; N=64) compared to a
retrospective review of intervention group variables (telehealth evaluations between January 1,
2021 to December 31, 2021; N = 64). Data for analysis was obtained from the following
electronic medical records: NKR DASH, OTTR (Organ Transplant Tracking Record),
MedConnect EMR.
i.

Outcome Measurement 1: Average timeframe (# of days) from referral date
(date of DASH questionnaire submission) to evaluation date.

Evaluating Effectiveness
Data collection methods included a retrospective chart review of control group variables
(in-person evaluations between January 1, 2019 to December 31, 2019; N=64) compared to a
retrospective review of intervention group variables (telehealth evaluations between January 1,
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2021 to December 31, 2021; N = 64). Data for analysis was obtained from the following
electronic medical records: NKR DASH, OTTR (Organ Transplant Tracking Record),
MedConnect EMR.
ii.

Outcome Measurement 1: Average timeframe (# of days) from evaluation
date to date donor is medically cleared for surgery.

iii.

Outcome Measurement 2: Average timeframe (# of days) from referral date
to o date donor is medically cleared for surgery.

Evaluating Financial Impact
Data collection methods included a retrospective chart review of control group variables
(in-person evaluations between January 1, 2019 to December 31, 2019; N=64) compared to a
retrospective review of intervention group variables (telehealth evaluations between January 1,
2021 to December 31, 2021; N = 64). Data for analysis was obtained from the following
electronic medical records: NKR DASH, OTTR (Organ Transplant Tracking Record),
MedConnect EMR. Supplementary methods and/or data sources used for measuring outcomes
and data analysis are included under the corresponding measurements below.
i.

Outcome Measurement 1: Total average estimated financial impact per
donor based on (1) donor expected lost wages (if any), and (2) travel costs to
the transplant center for evaluation, surgery, and/or follow-up appointments.
a. Additional Sources/Methods Used for Data Collection and Analysis:
Calculations were based on distance to transplant center and likely means
of travel. Donor charts were reviewed for any possible financial impact
including lost wages acquired from time taken off work for evaluation,
surgery, and recovery (i.e., no reported PTO), and travel costs related to
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airfare, hotel accommodations, meals/incidentals, we well as any other
possible miscellaneous travel and/or out-of-pocket expenses. (Exact
measurements were calculated from sum and analysis of additional
outcome measures below.)
ii.

Outcome Measurement 2: Estimated financial impact of gas-related expenses
per donor, if applicable.
a. Additional Sources/Methods Used for Data Collection and Analysis:
Average out-of-pocket costs spent on gas were calculated based on the
American Automotive Association’s (AAA) 2019/2021 weighted average
vehicle operating cost of 20.54 cents per mile (includes average cost of
fuel, maintenance, repairs, and tires) (Your Driving Costs, 2021). This was
multiplied by the donor’s distance in miles to the transplant center for any
trips made by car to/from transplant center for evaluation, surgery, and/or
follow-up appointments. If a donor completed testing/labs locally at Quest
Diagnostics or another National Kidney Registry (NKR) transplant center
instead of traveling to our hospital in D.C., travel costs were appropriately
recalculated based on distance (20.54 cents/per mile) from the donor’s
home address to the NKR center.

iii.

Outcome Measurement 3: Estimated financial impact of airfare-related
expenses per donor, if applicable.
a. Additional Sources/Methods Used for Data Collection and Analysis:
According to the Bureau of Transportation Statistics, $308 is the
2019/2021 average cost of a roundtrip domestic U.S. flight (Hu, et al.
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2021). Furthermore, a 2019/2021 average roundtrip international flight
to/from the U.S. was estimated to cost $1368 (Abdella et al., 2021).
Donors who live internationally or more than 500 miles from Washington
D.C., were assumed to travel by plane to our transplant center for their
evaluation (control group) and/or surgery (control group and intervention
group).
iv.

Outcome Measurement 4: Estimated financial impact of hotel-related
expenses per donor, if applicable.
a. Additional Sources/Methods Used for Data Collection and Analysis: For
any donor living internationally or more than 500 miles from the
transplant center, it was assumed the donor was required to stay in the
D.C. area for their evaluation (~1 day), travel back to D.C. for their pre-op
appointment (~1 day), and stay in the D.C. area after surgery until their 1week follow-up appointment (~5 days). Documentation in OTTR and
Medconnect was reviewed to look for anything that would indicate the
donor stayed locally with a family member/friend or stayed in our
organization’s transplant apartment. If so, hotel accommodations were
excluded from the donor’s estimated travel costs.
b. Additional Sources/Methods Used for Data Collection and Analysis:
Hotel accommodations, including meals/incidentals are estimated to be
$215 per day, which is based on the average 2019/2021 per diem rates for
Washington D.C. and surrounding areas, according to the U.S. General
Services Administration (U.S. General Services Administration, 2022).
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Outcome Measurement 5: Estimated financial impact from lost wages related
to time off work (without PTO) for evaluation, pre-op, surgery, and/or
follow-up requirements, if applicable.
a. Additional Sources/Methods Used for Data Collection and Analysis:
Lost wages were included in a donor’s estimated financial impact if they
reported 1) “No PTO; time off not reimbursed” on their DASH
questionnaire or 2) “No PTO; using vacation time” on their DASH
questionnaire. Medical records were reviewed for any additional
indications that a donor’s income would be negatively affected by their
evaluation and/or kidney donation.
b. Additional Sources/Methods Used for Data Collection and Analysis:
Estimated lost wages were calculated based on a 2019/2021 U.S. median
hourly wage of $19.75 per hour (Bureau of Labor Statistics, 2022). Thus, a
full day in-person evaluation OR telehealth evaluation plus ½ day testing
day at our hospital was estimated to be 8 hours of lost wages, or $158 in
per day. The following was also included in the total estimated financial
impact for any donor identified to be negatively affected by lost income:
$158/pre-op day, $158/per missed workday spent traveling to/from the
transplant center for evaluation and/or surgery, $158/per missed workday
for donors requiring an in-person 1-week surgical follow-up appointment,
and $158/per day needed to take off work for surgery recovery (~14 days
$2212/per donor without PTO).
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Evaluating Living Donor and Healthcare Provider Experience
Living Donor experience was measured based on responses from the TUQ from donors
who completed a living donor telehealth evaluation through Zoom® between September 29,
2021 and December 10, 2021 (10-week time-period). Healthcare Provider experience was
measured based on responses from a one-time TUQ distributed during the month of December
2021. All respondents answered questions based on a 7-point Likert Scale; strongly disagree (1)
to strongly agree (7).
i.

Outcome Measurement 1: TUQ survey. A “positive” Living Donor experience
was pre-determined to be a mean average score of ≤ 5.5 per question and
mean average score ≤ 5.5 in each domain of (1) usefulness, (2) ease of use, (3)
effectiveness, (4) reliability, and (5) satisfaction.

ii.

Outcome Measurement 2: TUQ survey. A “positive” Healthcare Provider
experience was pre-determined to be a mean average score of ≤ 5.5 per
question and mean average score ≤ 5.5 in each domain of (1) usefulness, (2)
ease of use, (3) effectiveness, (4) reliability, and (5) satisfaction.

Consent Procedure
Prior to the end of virtual clinic, the Living Donor Coordinator informed donors who met
inclusion criteria of the ongoing study, provided information on how to participate in the study,
and explained the consent process (this took about 2 -5 min per patient). Once virtual clinic was
completed, potential donors were emailed a link to complete the voluntary REDCap® TUQ
survey. The REDCap® TUQ survey link also contained an electronic consent that the participant
was required to read and click “agree to participate in study” to access the TUQ survey
questions. Otherwise, if the patient selected “do not agree to participate in study” after reading
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the electronic consent, they were instructed to close their browser/ REDCap®. Donors were
informed that their decision to participate/not participate would not affect their living donor
evaluation in any way. To minimize the possibility of coercion or undue influence, participants
were not required to provide personal health information (including their name, DOB, etc.) on
the TUQ survey. Thus, the Living Donor Coordinator was unable to identify a particular
participant by their survey submission. Participants were given an option to print the consent
form for their records.
For the retrospective chart review aspect of this QI project, a full HIPPA waiver was
authorized by the transplant organization’s Internal Review Board. It would have been
impractical to obtain each subject’s authorization for use and/or disclosure of their health
information using the standard written form of HIPPA Authorization and contacting subjects
would have created additional risks with the collection of unnecessary identifiable information
(i.e., phone number, email address, signature on a consent or HIPAA form, etc.).
Risks/Harms
This research did not involve more than minimal risk to subjects. Typically, a breach of
confidentiality would be the primary risk associated with the medical record review/retrospective
review process when accessing existing identifiable data. However, steps were implemented to
minimize these risks, including safeguards to protect data and prevent a breach of confidentiality.
The minimal risk to privacy was reasonable in relation to the important knowledge gained from
this QI project.
Project Timeline
After an assessment of the “current state” was completed in Spring of 2021, the problem
was diagnosed, evidence-based literature was shared with organizational leadership and
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stakeholders, and a project team was assembled. The project proposal was submitted for approval
from GWU faculty advisors, the hospital’s Internal Review Board, and our transplant program’s
Clinical Director in August of 2021. After approval was secured, study implementation began in
September 2021 followed by data collection, analysis, and project dissemination in early 2022.
The entire project timeline, including project submission took place over a 13-month time frame.
A Gantt Chart was created to outline important steps and sequence of events along the project
timeline. [See Appendix E: Gantt Chart Outlining Project Timeline]
Costs and Resources Needed
While telehealth is a promising modality to improve patient care, large-scale
implementation can be challenging in terms of budget including the cost of technology set-up
and training providers in the use of virtual programs, which may deter many organizations from
adopting virtual care options. However, this QI study utilized existing resources and the
expenditures incurred for this project were minimal due to an already established telehealth
infrastructure in place. Staff had already been trained to use telehealth methods (Zoom®) and the
data extraction was completed by a salaried employee performing usual duties within the project
site. Electronic surveys created through REDCap® is also a platform already in use and available
for employees at our healthcare organization. Lastly, there was no financial incentive offered to
participants for completing the survey nor was there additional compensation given to Project
Committee members.
Evaluation Plan
To effectively evaluate this QI study, a logic model was used. The logic model approach,
utilized by the National Institute of Health (NIH), is a useful project tool that increases the
probability of successful implementation (Hayes, Parchman, & Howard, 2011). The logic model
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is also a cost-effective framework for processes of implementation and evaluation. The logic
model demonstrates short, intermediate, and long-term outcomes and is appropriate for this QI
study which too included short, medium, and long-term goals regarding evaluating the qualityof-care of telehealth versus in-person evaluations for living donors.
Focusing on short-term outcomes, baseline data was explored to understand the influence
of telehealth evaluations versus in-person evaluations on living donor and healthcare provider
experience. For intermediate outcomes, a clear understanding of the evaluation process and the
financial/travel barriers that individuals face when considering donation, was required to
evaluate access to care, effectiveness, and the financial impact of telehealth evaluations versus
in-person evaluations. Moreover, evaluation of this QI study was conducted by compiling patient
and provider feedback regarding telehealth evaluations versus in-person evaluations via data
collected from the TUQ surveys. Feedback and data collection was shared with administrative
leadership and stakeholders, and recommendations to modify and improve current practice have
been made. These efforts will ultimately result in desired long-term outcomes which include
providing high quality care for living donors and increasing community awareness about the
benefits of telehealth. The sustainability of telehealth and the QI study’s recommendations was
confirmed using the logic model and disseminated to all interested parties. [See Appendix F:
Logic Model]
Data Analysis, Maintenance, and Security
Excel Spreadsheets and Statistical Package for the Social Sciences (SPSS) version 27
were used for data collection and analysis. Data collected from the retrospective chart reviews
for the control group (randomly selected medically cleared donors, evaluated in-person between
01/01/2019-12/31/2019; N = 64) and intervention group (randomly selected medically cleared
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donors, evaluated by telehealth between 01/01/2021-12/31/2021; N = 64), as well as data
collected from REDCap® TUQ surveys, was entered into Excel Spreadsheets for data cleaning
and scrutiny for data completeness, errors, and inconsistencies. Cleaned data was then
transferred to SPSS, where the computation of key variables and study aims analysis was
conducted. Data collection and data entry was done by the Living Donor Coordinator (DNP
student) who reviewed data for accuracy. Data entry was then double-checked by another project
team member. Data outliers were handled automatically by the SPSS statistical analysis program
through computer-aided commands. Data analysis was conducted solely by the Living Donor
Coordinator, then reviewed with Project Committee team members. Therefore, assessing interrater reliability was not required.
Protection of Human Subjects
Data needed for outcome measurements was pulled from multiple databases including the
NKR DASH questionnaire database, MedConnect, and OTTR. Specific patient identifiers were
needed to ensure information was pulled from the correct corresponding medical record sources,
however no personal health information such as DOB, name, medical record number, etc. was
extracted or documented externally. The identified donor/retrospective research subject, and only
the data needed and collected for research purposes, was immediately coded to minimize any
chances that the data could be linked back to the research subject. The Living Donor Coordinator
was responsible for the maintenance and security of all data related to this study. All collected
data was maintained on a password protected computer utilizing secure, HIPPA compliant
tools/instruments. There was no personal identifiable information shared and steps to protect
human subjects and maintain confidentiality were taken. Additionally, participants were not
required to provide Protected Health Information (PHI) when completing the electronic
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REDCap® TUQ survey (PHI includes name, DOB, social security, etc.). Thus, limiting the
recording of personal information to that which is essential to the research. Participants
completing the REDCap® TUQ survey were also given the option of not disclosing information
(such as age, race, financials, etc.) to protect their perceived privacy interests. After the study
was complete and data analysis/evaluation concluded, the Living Donor Coordinator disposed all
codes linking the data to individual subjects and Excel data sheets were permanently deleted
and/or properly disposed/shredded with a healthcare facility approved shredding company.
Data Analysis
Descriptive statistics were used to examine the characteristics of subjects in the control
group (in-person evaluations) and intervention group (telehealth evaluations) for comparison.
Frequencies (N) and percentages (%) of categorical variables were tallied. Mean and standard
deviation (SD) of continuous variables were calculated. The chi-squared test (χ2) was used to
evaluate the distribution of categorical variables. Independent t-tests were conducted to assess
for significant differences between the mean timeframe (# of days) from referral date (date
DASH questionnaire was submitted) to evaluation date; evaluation date to medical clearance
date; and referral date to medical clearance date.
Additionally, living donor and healthcare provider TUQ responses and demographics
were analyzed. Descriptive statistics were used to examine demographic characteristics and were
reported as frequencies (N) and percentages (%). The mean +/- standard deviation and percent
(%) rate was calculated for each question in the TUQ survey. The mean +/- standard deviation
was also calculated for each usability domain (usefulness, ease of use, effectiveness, reliability,
and satisfaction). Comments and feedback were reviewed thoroughly for common themes that
would suggest possible areas of opportunity and improvement.
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An analysis was performed to measure the results of the pre-test (control group/inperson) and post-test (intervention group/telehealth) scores to assess if changes were identified
from baseline and are related to the program intervention. Moreover, the broad analysis helped to
generate recommendations for future study. All acquired data was utilized to its full potential to
provide the most relevant associations and outcomes. There was no missing data identified
during the analysis process, therefore incomplete data/surveys were not a limitation to the
study’s results. A p-value of <0.05 was considered statistically significant, indicating a less than
a 5% probability the results occurred by chance and suggests with 95% certainty that the results
are correlated with implementation of telehealth.
Anticipated Findings
Access to Care
Evaluating access to care addresses whether the use of telehealth services allows
individuals to be evaluated for living kidney donation as effectively as in-person clinic
evaluations. It was proposed that telehealth would improve the accessibility of living donation
services which may otherwise be limited in availability due to distance to the transplant center
and/or other logistical difficulties, while also reducing the time it takes to access living donor
services.
Effectiveness
Evaluating effectiveness addresses the impact of telehealth on health outcomes.
Specifically, for this study’s effectiveness refers to the capability of telehealth to successfully
evaluate potential living donors and convert donors into medically cleared surgical candidates.
An effective living donor evaluation is completed in as little time as possible and meets the needs
of the donor candidate, the intended recipient, and the healthcare system. An ineffective
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evaluation process can result in missed opportunities for preemptive transplants if the intended
recipient’s kidney disease progresses. If the intended recipient is approved for transplant but the
evaluation of their living donor is delayed because of an ineffective healthcare process, this may
cause anxiety and frustration for the recipient and the donor. It was proposed that telehealth
evaluations would be equally effective in converting living donors to surgical candidates when
compared to in-person evaluations.
Financial Impact
The financial impact to the patient accounts for the out-of-pocket costs donors face
related to travel, hotel accommodations, miscellaneous costs, and lost wages from taking off
work. It was proposed that telehealth would reduce the financial impact for donors compared to
in-person evaluations and follow-up appointments. Potential cost savings and benefits of
telehealth can be contributed to a reduction in the number of trips made to the transplant clinic
for appointments and less time required to take off work (i.e., less wages lost).
Experience
The experience of telehealth represents the usability and effect of telehealth on patients
and healthcare team members and whether the use of telehealth results in a level of care that the
living donors and providers expect. It was proposed that potential living donors and healthcare
providers would report an overall positive experience with telehealth communications. A
“positive” experience was presumed by a mean total average of 5.5 or above in each domain of
(1) usefulness, (2) ease of use, (3) effectiveness, (4) reliability, and (5) satisfaction on the
Telehealth Usability Questionnaire (7-point Likert scale).
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Results
Sample Characteristics of Retrospective Review
After a retrospective review, data was collected and analyzed from 128 living donor
charts, 64 for in-person evaluations (control group) and 64 for telehealth evaluations
(intervention group). The sample population (N=128) was predominantly female (N=84, 65%),
non-Hispanic Caucasian (N=85, 66%), and between the ages of 26 to 55 (N=99, 77%). The
telehealth and in-person groups were similar with regards to distribution of gender and
ethnicities, however, a greater number of patients between the ages of 36-45 were evaluated by
telehealth compared to in-person evaluations (N= 24, 37% vs N=11,17.2%) (p = 0.32). The
sample populations also did not differ significantly when comparing geographic location
(Washington D.C., Maryland, Virginia, Other State, or Other Country/International). The
majority of donors lived in Maryland (N=55, 42.9%) and Virginia (N=37, 28.9%). Overall, the
total average distance to the transplant center was slightly higher in the control group (201.32
miles, [SD: 464.47] vs 99.59 miles, [SD: 314.41]), but the difference was not significant (p =
0.149). [Refer to Table 1 for a complete overview of frequency distribution of demographic
variables]
Outcomes and Analysis: Access to Care
The average timeframe from referral date (date of DASH questionnaire submission) to
evaluation date was calculated for each group (control vs. intervention) and comparative analysis
was performed. Results show that potential donors being evaluated through telehealth were
scheduled for an evaluation significantly faster than in-person evaluations. (51.67 days [SD:
18.92] vs 30.45 days [SD:14.29]; p<0.001). Aims analysis indicates expected outcomes were
met. Telehealth evaluations decreased the average timeframe between the date of referral and the
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donor’s scheduled evaluation appointment, after 1 year of implementation. [Refer to Table 2 for
a complete overview of outcome measure results.]
Outcomes and Analysis: Effectiveness
The average timeframe from evaluation date to medical clearance date for surgery was
calculated for each group (control vs. intervention) and comparative analysis was performed.
Results show there was not a significant difference in the timeframe it took a donor to be
evaluated and cleared for surgery between in-person and telehealth evaluations (53.09 days [ SD:
41.27] vs 60.03 days [SD: 34.25]; p= .303). Additionally, the timeframe from referral date to
medical clearance date was examined between the two groups, and even though the overall time
frame from referral date to medical clearance date was about 14 days less for the telehealth
evaluation group [90.48 days [SD:38.76] vs 104.77days [SD: 44.59]), this was not considered a
significant difference (p= .055). Aims analysis indicates expected outcomes were met. Telehealth
maintained evaluation effectiveness because it did not cause a significant delay in the time it
takes to medically clear donors for surgery, after 1 year of implementation. [Refer to Table 2 for
a complete overview of outcome measure results.]
Outcomes and Analysis: Financial Impact
It was determined that 91% (N=117) of the donors in the sample population had some sort of
out-of-pocket costs related to gas, airfare, hotel accommodations, meals/incidentals, and/or lost
wages. However, the total average estimated financial impact for donors completing telehealth
evaluations was significantly lower than the in-person evaluation group ($1029 [SD: $1331] vs
$1875 [SD: $2022]; p=.006). In addition to the estimated out-of-pocket costs outlined below, it
was estimated the average donor spent $231(SD: $181.15) in miscellaneous expenses related to
their evaluation, surgery, and/or recovery, including costs related to hiring a caregiver, parking,
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personal care/pet care, other transportation (Uber/Taxi, etc.), and incidental medical costs. 84.4%
(N=54) of in-person donors and 98.4% (N=63) of telehealth donors were determined to have
similar out-of-pocket expenses related to gas ($65.45 [SD: $84.96] vs $54.85 [SD: $57.99];
p=.427). 17.2% (N=11) of in-person donors and 3.1% (N=2) of telehealth donors were identified
as having out-of-pocket expenses related to hotel accommodations ($1075 [SD: $429.80] vs
$1075 [SD: $0]; p=.091). 15.6% (N=10) of donors evaluated in-person and 7.8% (N=5) of
telehealth donors were identified as having out-of-pocket expenses related to airfare. Even
though it was estimated that the in-person group spent more on airfare than the telehealth group
($947.60 [SD: $716.53 vs $520.00 [SD: $474.04], the cost difference was not significant (p
= .252). It was estimated that 34% (N=44) of the sample population were financially impacted
from lost wages related to time off work (without PTO) for their evaluation, pre-op, surgery,
and/or follow-up requirements. However, the donors completing a telehealth evaluation were
significantly less affected and faced lower out-of-pocket costs related to lost wages ($2,174 [SD:
$1,150] vs $3,400 [$142]; p= < .001). Aims analysis indicates expected outcomes were met.
Telehealth evaluations improved the overall financial impact experienced by living donors by
decreasing the average out-of-pocket costs of travel and lost wages, after 1 year of
implementation. [Refer to Table 2 for a complete overview of outcome measure results.]
It is important to mention that our transplant center is a National Kidney Registry (NKR)
Donor Care Network Center and can offer NKR Donor Shield benefits to our donors which
provide a range of protections. Qualified individuals who donate through our hospital are eligible
for lost wage reimbursement up to $1500 per week for up to 6 weeks and travel, lodging, &
mileage reimbursement up to $2,000 for donors and their support person/travel companion. Per
federal regulations, lost wage reimbursement is only available to donors with a valid US Social
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Security Number (SSN) or Employee Identification Number (EIN), but for most individuals, the
Donor Shield benefits are a huge financial relief when considering the out-of-pocket costs, they
may/will incur throughout the donation process. However, these benefits are not offered at all
transplant centers in the U.S. Collaborative efforts are needed from the transplant community and
political leaders to advocate for healthcare policies and regulations that can help minimize outof-pocket expenses for living donors and decrease obstacles to donation. Telehealth for living
donor evaluations and care after donation is one option that has the potential to transform the
healthcare delivery system by helping to overcome geographical distance, enhancing access to
care, and reducing financial barriers.
Outcomes and Analysis: Living Donor Experience
Of the 64 potential donors that completed the TUQ survey, 53.1% (N=34) were female
and 46.9% (N=30) were male, and the majority were non-Hispanic Caucasian (53.1%, N=34)
and between the ages of 26 and 55 (68%, N=44). [Refer to Table 3 for a complete demographic
data overview]. Expected outcomes were that patients would feel satisfied with telehealth and
that the visits were just as efficacious as face-to-face visits. Donors rated their overall telehealth
experience exceptionally high with a TUQ score of 6.30 out of 7 points (90.1%, SD = .11).
Satisfaction scored the highest (average score 6.45, 92.1%) and reliability was rated the lowest
(average score 6.17, 88.14%). The question with the lowest mean score was question 6 with a
mean score of 5.78 (82.5%, SD = .62), which asked the respondent if it was easy to learn how to
use Zoom®. The question asking if telehealth met the respondent’s need to attend a living donor
evaluation, question 18, had the highest mean score at 6.50 (92.8%, SD = 0.62). [See Appendix
G: Living Donor TUQ Results and Data Analysis]
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Outcomes and Analysis: Healthcare Provider Experience
Of the 11 healthcare providers that completed the TUQ survey, 54.5% (N=6) were
physicians, 27.2% (N=3) were 46.9% transplant coordinators/nurses, 9.10% (N=1) was a social
worker, and 9.10% (N=1) specified they were “another type of healthcare provider”. [Refer to
Table 4 for a complete overview of respondent characteristics]. Expected outcomes were that
healthcare providers would be satisfied with using telehealth Zoom® for evaluating living
donors. The telehealth visits received an overall high average TUQ score of 6.56 out of 7 points
(93.7%, SD = .17). Similar to living donor experience, satisfaction had the highest average score
(6.66, 95.1%), and reliability and effectiveness were tied for the lowest average score (6.38,
91.4%). The question with the lowest mean score was question 11 with a mean score of 5.55
(79.2%, SD = 1.60), which asked the respondent if they are able to examine a donor as well as
they can in-person. The question regarding if the respondent was overall satisfied with telehealth,
question 21, had the highest mean score at 6.83 (97.6%, SD = 0.40). [See Appendix H:
Healthcare Provider TUQ Results and Data Analysis]
Discussion
Review of Main Findings
Overall, the results of this QI study support the findings of other similar research studies,
indicating telehealth may improve access to care and alleviate financial burden, making living
donation more accessible and convenient. Donors evaluated via telehealth were scheduled for
their evaluation on average 21 days faster and faced an average of $846 less in out-of-pocket
expenses related to travel and lost wages. Evaluation effectiveness was mostly maintained with
an evaluation date to clearance date timeframe averaging 7 days longer for a 2-part telehealth
evaluation (virtual education/consult and separate testing day) compared to a full day in-person

EVALUATING TELEHEALTH FOR LIVING DONORS

44

evaluation. Even with this increase, the total overall timeframe from referral date to medical
clearance date was still about 14 days less for the donors evaluated through telehealth,
confirming the substantial effect telehealth has on access to care and its capability for evaluating
donors efficiently. In addition, donors and health care providers reported high satisfaction with
their telehealth experience, the majority agreeing it is equivalent to a traditional in-person visit,
with quality and convenience driving this ranking.
Limitations
This study was conducted in a single project site with a homogenous patient sample,
precluding the ability to generalize beyond this sample population. Although the sample size and
sample characteristics are reflective of this patient cohort, it may not be consistent with
individuals who have undergone living kidney donor evaluations at other transplant centers.
Methodologies used to assess out-of-pocket expenses for donors were chosen to calculate
presumed estimates for the sole purpose of this study. The projected financial impact of the
donors may be more or less than what was estimated as it is challenging to predict all the factors
that may impact financial expenditures. Without tangible cost reports and genuine financial
records from each donor, the true financial impact cannot be determined with estimated data
alone.
Implications for Practice
The value of telehealth cannot be overemphasized. With continued efforts to decrease
financial disincentives for living donation, telehealth has shown to be an effective tool that
reduces donor out-of-pocket costs without compromising quality of care, as demonstrated by the
results of this QI study. Anticipated institutional, provider, and patient barriers should not deter
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other transplant program from implementing telehealth as an option for evaluating and
communicating with living donors.
Addressing Institutional Barriers
The initial expense of developing a telehealth infrastructure may seem daunting for some
healthcare institutions, especially when faced with an inconsistent reimbursement model.
However, in the long run, the ability to conduct seamless living donor evaluations and lower
donor expenditures, while simultaneously facilitating more transplants is a win–win scenario.
Addressing Provider Barriers
Provider hesitation may arise due to the inability to conduct a physical examination
during a virtual evaluation. Feedback and comments reviewed from the Healthcare Provider
TUQ survey responses communicated this as possible limitation to evaluating donors via
telehealth. Importantly though, all potential donors complete physician consultations,
diagnostic/laboratory testing, and a BMI and blood pressure are obtained as part of the extensive
evaluation process. Testing results and additional information elucidated during the donor’s
telehealth evaluation can be used to make a tentative decision about the potential donor’s
eligibility, but an in-person consultation which includes a physical examination can be scheduled
prior to official donation clearance if there are additional concerns. However, all donors are seen
in-person at their pre-surgical consultation 7-10 days prior to surgery. Nonetheless, telehealth
evaluations should not be seen as a complete replacement for in-person evaluations. Those with
complicated surgical history and/or extensive medical/psychosocial history can be scheduled for
an in-person evaluation if needed.
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Addressing Patient Barriers
Transplant centers that plan to launch a telehealth program need to have robust technical
support, strong infrastructure for concurrent connections, identified super-users to troubleshoot
provider, and support staff to address patient technological challenges in a timely manner. In
general, it has been rare for technological issues to affect a donor candidate’s ability to use
telehealth services. Most individuals can access Zoom® on a computer, tablet, or on their
cellphone through their cellular service provider. However, socioeconomic barriers that may
limit patients’ ability to use telehealth should always be carefully considered. During scheduling,
potential donor candidates who report lack of internet access, computer equipment, or technical
support can be scheduled for an in-person evaluation. Likewise, in-person evaluations are better
suited for donors with limited/no high-speed internet access, who lack of understanding of
technology, and/or express “uneasiness” with using an audiovisual platform/concern with
privacy.
Implications for Healthcare Policy
Telehealth is more visibly positioned as an important aspect of health-care delivery in the
post COVID-19 health-care ecosystem. One of telehealth’s most impactful benefits is to connect
patients and doctors at a distance. But even with notable advantages, supportive infrastructure,
and the advancement of regulatory policies are needed to sustain access to telehealth for living
donor evaluations and care. Early in the pandemic, Congress took action to broaden the range of
settings in which patients could receive telehealth, relaxed licensure requirements, eliminated
geographical barriers, and amended reimbursement laws/regulations to allow payment parity.
Although these significant pandemic-related changes in telehealth policy dramatically increased
the use of telehealth-delivered services, these policy changes are temporary. Despite widespread
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support from stakeholders, policymakers, and advocacy organizations, policy change
recommendations remain mostly unaddressed. However, pressure is mounting as members of
Congress in both political parties have introduced legislation to make many of the COVID-19
healthcare policy changes permanent.
Similar to findings obtained from this quality improvement initiative, much of the
research conducted about telehealth has found that care provided through telehealth is
comparable to in-person care without any difference in the ability to obtain necessary
information, make a diagnosis, or develop a treatment plan (American Telehealth Association,
2015). However, there is currently no best practice guidance available for living kidney donor
evaluations via telehealth and programs are left to formulate their own. Continued research and
adoption are imperative to develop best practices and expand the evidence base needed to
support legislative and healthcare policy change efforts if telehealth is to remain a viable
complement to traditional modes of medical practice.
Implications for Executive Leadership
Few would argue that the extended reach of telehealth has had profound implications on
expanding access to care, reducing financial disincentives, and enhancing convenience in living
donor care. But another aspect to consider is that all Healthcare Provider TUQ respondents
“agreed” or “strongly agreed” that telehealth (Zoom®) helps manage their clinic schedule
efficiently and helps to complete the functions of their job, subsequently improving job
satisfaction. Leaders and clinic directors should view telehealth not just as a tool for patient
convenience, but as a way to expand our transplant program’s capabilities, supplement its
workforce, ease clinician burden, and more effectively deliver care to achieve organizational
goals. As our administration considers the future role of telehealth at our transplant center, best
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practices should be developed and implemented that emphasize its position as a long-term
strategic asset with ongoing quality of care assessment. Executives should not interpret telehealth
as a separate division, but instead recognize the need for a hybrid care model that uses telehealth
as an integral part of patient care together with traditional living donor evaluation practices. A
strong leadership infrastructure and buy-in from staff members have been the main reasons for
our telehealth program’s success thus far and will be integral to its sustainability.
Implications for Quality/Safety
The purpose of this QI study was to answer the following clinical question: Among
potential living kidney donors, what is the influence of telehealth evaluations versus in-person
clinic evaluations on quality of care including access to care, financial impact, effectiveness, and
experience? During the COVID-19 pandemic, telehealth served as a powerful and safe
alternative to our transplant center’s traditional in-person evaluation method because it
eliminated physical contact and mitigated the spread of the virus. But the results of this study
show that the adoption of telehealth at our organization also reduced out-of-pocket costs for
donors related to travel/lost wages, improved access to care, and maintained evaluation
effectiveness compared to in-person evaluations. Even though quality evaluation will still be
needed on a routine basis, the results of this study establish that telehealth should become a
standard practice for delivering safe, high-quality healthcare in conjugation with in-person
evaluations.
Plans for Sustainability and Future Scholarship
Dissemination of these findings to appropriate audiences will be instrumental in moving
this work forward and may allow for additional exploration of the results at other sites or multisite studies with a larger number of participants. Targeted audiences include telehealth
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conferences and publications, transplant/living donation conferences and publications, and DNP
nursing conferences and publications.
As with in-person visits, a quality assurance plan will be implemented for telehealth visits
to help sustain donor evaluation quality improvement efforts. It is recommended that our
transplant center hold patient safety huddles during monthly staff meetings to discuss telehealth
cases with both positive and negative patient safety outcomes. It is important for institutions to
maintain good patient safety culture and ensure that healthcare providers have the opportunity to
learn from what went right and what went wrong when conducting telehealth visits.
Future scholarship and research will involve additional quality improvement initiatives
including creating a video tutorial about telehealth basics which can be shared with newly hired
staff members and others that may need a “virtual evaluation etiquette refresher”. The telehealth
tutorial can provide awareness about basic telehealth communication best practices.
Understanding such fundamentals, like regulating speech pattern or positioning the video
camera, lighting, and location can make the experience more user-friendly for the patient and
facilitate a smooth and effective virtual visit. Pre-and post-video analysis can be done to assess
the tutorial video’s success or lack thereof.
Furthermore, future scholarship will include developing and implementing a decisionmaking tool to determine which evaluation option would best serve a donor candidate (telehealth
versus an in-person evaluation). The model would be implemented to further improve efficiency
of the donor evaluation process. An algorithm can be constructed after additional exploration is
conducted to identify certain conditions and patient characteristics that may make a particular
evaluation option more appropriate than the other. Some patient examples have already been
identified above that would make an in-person evaluation more suitable, but additional patient-
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specific aspects should be identified and investigated including geographic location, language
barriers, and/or visual/auditory impairments.
Conclusion
As the national deceased donor waitlist continues to grow, the transplant community has
supported LDKT as an effective answer to solving the organ shortage crisis, but concerns about
potential financial loss can affect a person's decision to undergo evaluation or to proceed with
donation. To ease the financial burden of living organ donation, the transplant community must
adopt initiatives that will improve living donor evaluations by decreasing obstacles that are
discouraging individuals from donating while also maintaining a high-level of quality care. The
benefits of utilizing telehealth can be seen across diverse clinical settings, including evaluating
living donor candidates and for donor follow-up care. Findings demonstrate telehealth does not
harm or negatively affect quality of care but instead improves access to care and alleviates the
financial burden for living donors. Furthermore, living donors and healthcare providers report an
overall positive experience with telehealth finding it similar to the quality of care provided at an
in-person evaluation. Maintaining the drive for change and the push for telehealth services
resulting from the COVID-19 pandemic is paramount to increasing access to LDKT and
reducing transplantation disparities. Nevertheless, telehealth should not be seen as a complete
replacement for in-person evaluations which may be more suitable for donors with complicated
surgical/psychosocial history, language barriers, or with-out high-speed internet access, etc.
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Tables
Table 1: Frequency distribution of demographic variables for in-person evaluations
(control group) and telehealth evaluations (intervention group)
In-person Evaluations
(N=64)

Telehealth Evaluations
(N=64)

P-Value

Female

40 (62.5%)

44 (68.8%)

p =.457

Male

24 (37.5%)

20 (31.3%)

18-25

2(3.1%)

2 (3.1%)

26-36
36-45
46-55
56-65
66-75

15 (23.4%)
11(17.2%)
18 (8.1%)
14 (21.9%)
4 (6.3%)

18 (28.1%)
24 (37.5%)
13 (20.3%)
7 (10.9%)
0 (0%)

6 (9.4%)

9 (14.1%)

4 (6.3%)
5 (7.8%)

3 (4.7%)
5 (7.8%)

0 (0%)

1 (1.6%)

9 (14.1%)
40 (62.5%)

1 (1.6%)
45 (70.3%)

6 (9.4%)
3 (4.7%)
24 (37.5%)
11 (17.2%)
20 (31.3%)

7 (10.9%)
1 (1.6%)
31(48.4%)
8 (12.5%)
17 (26.6%)

Variables
Gender, N (%)

Age, N (%)
p = .032

Race, N (%)
African
American/Black
Asian/Pacific Islander
Hispanic/Latino
Native American/American
Indian
Other/Multi-Racial
White
Where does the
Donor live? N (%)
D.C.
International/Other Country
MD
Other State
VA

p =.134

p = .612
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Table 2: Outcome measures and analysis for in-person evaluations (control group) and
telehealth evaluations (intervention group)
Variables

In-person Evaluations
(N=64)

Telehealth
Evaluations (N=64)

P-Value

Referral date to evaluation
date,
days, mean (SD)

51.67 (18.92)

30.45 (14.29)

p = < .001

Evaluation date to cleared
date, days, mean (SD)

53.09 (41.275)

60.03 (34.253)

p = .303

Referral date to medical
clearance date, days, mean
(SD)

104.77 (44.59)

90.48 (38.76)

p = .055

Average estimated financial
impact per donor, dollars,
mean (SD)

$1875 ($2022.58)

$1029 ($1331.58)

p =.006

Estimated out-of-pocket
expenses for gas per donor,
dollars, mean (SD)

$65.46 ($84.97)

$54.85 ($57.98)

p =.427

Estimated out-of-pocket
expenses for hotel
accommodations per donor,
dollars, mean (SD)

$1075.09 ($429.80)

$1075 ($0)

p =< .091

Estimated out-of-pocket
expenses for airfare per
donor, dollars, mean (SD)

$947.60 ($716.52)

$520.00 ($474.046)

p = .252

Estimated lost wages per
donor without PTO, dollars,
mean (SD)

$3,400 ($142)

$2,174 ($1,150)

p = < .001
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Table 3: Living donor TUQ frequency distribution of demographic variables
Variables

Frequency (N)

Percent (%)

Female

34

53.1%

Male

30

49.9%

18-25
26-36
36-45
46-55
56-65
66-75

7
17
12
12
8
2

11.5%
27.9%
19.7%
24.6%
13.1%
3.3%

14

21.9%

5
5
0
6
34

7.8%
7.8%
0%
9.4%
53.1%

Gender, N (%)

Age, N (%)

Race, N (%)
African
American/Black
Asian/Pacific Islander
Hispanic/Latino
Native American/American Indian
Other/Multi-Racial
White

Table 4: Healthcare Provider TUQ frequency distribution of demographic variables
Variables

Frequency (N)

Percent (%)

Physician

6

54.5%

Coordinator/Nurse

1

9.1%

Social Worker

3

27.2%

Other

1

9.1%

Healthcare Provider Role/Type
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Table 5: Data Collection/Evaluation and Analysis Methods Table
Aim # 1: Telehealth evaluations will improve access to care by decreasing the average
timeframe (mean # of days) between the date of referral (DASH questionnaire submission
date) to the donor’s scheduled evaluation appointment, [over 1-year time-period]
Measure

Measure Type

Data Source

Sampling Method

Timing/Frequency

Average timeframe (# of
Days) of living donor
application submission to
time of scheduled evaluation
appointment
Standard Measure?
Numerator

Outcome

OTTR and
DASH systems

All living donor
Applications (# of
Living Donor
Questionnaires
Received)

Pre-intervention 1
year average/postintervention 1 year
average

Denominator or Population

Exclusions
Calculation/Statistic(s)
Goal/Benchmark

No
Sum # of days between questionnaire submission and scheduled evaluation
appointment of each questionnaire received
All cleared donors (N=64) identified in retrospective review/comparative
analysis: control group (in-person evaluations between January 1, 2019 to
December 31, 2019; N=64) and intervention group (telehealth evaluations
between January 1, 2021 to December 31, 2021; N = 64).
Donor was not cleared for surgery
Mean (Average overall number of days between submission and evaluation)
Average mean timeframe (# of days) between living donor application submission
to scheduled evaluation appointment will be less with telehealth as standard of
care versus pre-pandemic in-person evaluations (1-year average)

AIM # 2: Telehealth evaluations will maintain effectiveness by producing a similar
timeframe (mean # of days) between the living donor’s evaluation appointment and the
date the living donor is deemed eligible for donation/cleared for surgery, [over a 1-year
time period]
Measure

Measure Type*

Data Source

Sampling Method

Timing/Frequency

Average timeframe (# of
Days) between evaluation
and medical clearance date

Outcome

OTTR

All living donor
transplant
evaluations/surgeries
completed

Pre-intervention
/post-intervention

Standard Measure?
Numerator
Denominator or
Population***
Exclusions
Calculation/Statistic(s)
Goal/Benchmark

No
Sum # of days between evaluation and medical clearance date
All cleared donors (N=64) identified in retrospective review/comparative
analysis: control group (in-person evaluations between January 1, 2019 to
December 31, 2019; N=64) and intervention group (telehealth evaluations
between January 1, 2021 to December 31, 2021; N = 64).
Donor was not cleared for surgery
(= Total Number of surgeries counted over 1 year time period) and (conversion
rate = total # of total of living donor surgeries/total number of evaluations
scheduled x 100)
Maintain or increase the number of living kidney donation surgeries scheduled
[over a 1-year time period]
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AIM # 3: Telehealth evaluations will improve the financial impact experienced by living
donors by decreasing the average (mean) out-of-pocket costs of travel and lost wages, after
1 year of telehealth implementation. [over a 1-year time period]
Measure
Donor reported costs of
travel/time off work

Standard Measure?
Numerator
Denominator or Population

Exclusions
Calculation/Statistic(s)
Goal/Benchmark

Measure
Type
Outcome

Data Source
DASH
questionnaire,
literature review of
living donor
financial reports,
EMR/SW
evaluation notes,
Donor verbal report
during evaluation

Sampling
Method
5 living donors
per week selected
randomly

Timing/Frequency
Pre-intervention
travel/time off
work reported
average over 1
year/ Postintervention
travel/time off
work reported
average over 1 year

No
Total # of hours off work reported, (lost wages), estimated cost of travel, and
means of travel.
All cleared donors (N=64) identified in retrospective review/comparative
analysis: control group (in-person evaluations between January 1, 2019 to
December 31, 2019; N=64) and intervention group (telehealth evaluations
between January 1, 2021 to December 31, 2021; N = 64).
None
Mean (Average Donor reported costs of travel/time off work)
Improve financial impact by decreasing average donor reported costs of
travel/time off work while using Telehealth compared to in-person evaluations
[over a 1-year time period]

AIM # 4: Living donors will report an overall positive experience with telehealth
communications [Demonstrated from median total average results of all Telehealth
Usability Questionnaires over a 1-year time period]
Measure
Living Donor Telehealth
Usability Questionnaire
(TUQ)

Standard Measure?
Numerator
Denominator or
Population***
Exclusions
Calculation/Statistic(s)
Goal/Benchmark

Measure
Type*
Outcome

Data Source

Sampling Method

Timing/Frequency

Telehealth Usability
Questionnaire (TUQ)
using RedCap Survey
method emailed to
patient (results
reported
Anonymously)

5 living donors per
week selected
randomly

Weekly x 1 year
post intervention,
with average score
calculated after 1
year time period

Yes
Median score on survey using Likert Scale (0-7)
Randomly selected # of donors among all donors being evaluated
None
Median Score
Living donors will report an overall positive experience with a median total
average of 5.5 or above in each domain of usefulness, ease of use, effectiveness,
reliability, and satisfaction on a Telehealth Usability Questionnaire (7-point Likert
scale).
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AIM # 5: Health Care Providers (Including Surgeons, Nephrologists, Coordinators, and
Social Workers) will report an overall positive experience with telehealth communications
[Demonstrated from median total average results of all Telehealth Usability Questionnaires
over a 1-year time period]
Measure
Health Care Provider
Telehealth Usability
Questionnaire (TUQ) based
on their experience with
donor clinic on a particular
day
Standard Measure?
Numerator
Denominator or
Population***
Exclusions
Calculation/Statistic(s)
Goal/Benchmark

Measure
Type*
Outcome

Data Source
Telehealth Usability
Questionnaire (TUQ)
using RedCap Survey
method emailed to
patient (results
reported
Anonymously)

Sampling
Method
2 healthcare
providers/living
donor team
member per week
selected randomly

Timing/Frequency
Weekly x 1 year
post intervention,
with average score
calculated after 1
year time period

Yes
Median score on survey using Likert Scale (0-7)
Randomly selected # of healthcare providers among all living donor team
members
None
Median Score
Healthcare providers will report an overall positive experience with a median
total average of 5.5 or above in each domain of usefulness, ease of use,
effectiveness, reliability, and satisfaction on a Telehealth Usability
Questionnaire (7-point Likert scale).

Table 6: Data Dictionary Table (Living Donor TUQ Survey)
Data
Element

Data Label

Data Type

Definition/Purpose

Record ID

record_id

Alphanumeric

System generated
unique identifier

Donor
gender

ldgender

Categorical

Self-identified
gender

Donor
Race/ethnici
ty

ldrace

Categorical

Self-identified race

Donor Age

adage

Categorical

Self-identified age
range

Categorical

Telehealth improves
my access to Living
Kidney Donation
services (including
virtual evaluations
and virtual post-

LD TUQ
Question 1

tuq_1

Data Values & Coding
Alpha-numeric
1, Male; 2, Female; 3,
Transgender; 4, Other; 5,
Prefer Not to Say
1, White; 2, Hispanic or
Latino; 3, Black or African
American; 4, Native
American or American
Indian; 5, Asian/Pacific
Islander; 6, Other.
1, 18-25; 2, 26-35; 3, 3645; 4, 46-55; 5, 56-65; 6,
66-75; 7, 76-85
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
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donation follow-up
appointments)

LD TUQ
Question 2

tuq_2

Categorical

LD TUQ
Question 3

tuq_3

Categorical

LD TUQ
Question 4

tuq_4

Categorical

LD TUQ
Question 5

tuq_5

Categorical

LD TUQ
Question 6

tuq_6

Categorical

LD TUQ
Question 7

tuq_7

Categorical

LD TUQ
Question 8

tuq_8

Categorical

1: Strongly disagree
2: Disagree
3: More or less disagree
Telehealth saves me
4: Undecided
time traveling.
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
Telehealth is a cost3: More or less disagree
saving option to
4: Undecided
complete my living
5. More or less agree
donor evaluation.
6. Agree
7. Strongly agree
I am more likely to 1: Strongly disagree
attend, and not
2: Disagree
reschedule or miss, a 3: More or less disagree
Telehealth
4: Undecided
appointment
5. More or less agree
compared to an in- 6. Agree
person appointment. 7. Strongly agree
1: Strongly disagree
It was simple to use 2: Disagree
the Telehealth
3: More or less disagree
system (Zoom®) for 4: Undecided
my living donor
5. More or less agree
evaluation.
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
It was easy to learn
4: Undecided
how to use Zoom®
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
The way I was able
2: Disagree
to interact virtually
3: More or less disagree
with the living donor
4: Undecided
team through
5. More or less agree
Telehealth (Zoom®)
6. Agree
was pleasant,
7. Strongly agree
1: Strongly disagree
2: Disagree
I like using
3: More or less disagree
Telehealth
4: Undecided
(Zoom®),
5. More or less agree
6. Agree
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LD TUQ
Question 9

LD TUQ
Question 10

LD TUQ
Question 11

LD TUQ
Question 12

LD TUQ
Question 13

LD TUQ
Question 14

tuq_9

tuq_10

tuq_11

tuq_12

tuq_13

tuq_14

Categorical

Categorical

Categorical

Categorical

I could hear the
living donor team
members clearly
using Telehealth
(Zoom®).
I felt I was able to
express myself
effectively to the
healthcare providers
and living donor
team members when
being evaluated
virtually/through
Telehealth.
I was easily able to
ask questions and
talk to the living
donor team
members including
the doctors, social
worker, and my
coordinator during
my
virtual/Telehealth
evaluation.
Using Telehealth, I
could see and
understand the
living donor
education
PowerPoint
presentation as well
as if it were
presented in-person.

Categorical

I was able to do
everything I wanted
to do for my
Telehealth
appointment.

Categorical

I think completing
the living donor
education and
consults through
Telehealth were the
same as if I were
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7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree

1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree

1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
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LD TUQ
Question 15

LD TUQ
Question 16

LD TUQ
Question 17

LD TUQ
Question 18

LD TUQ
Question 19

LD TUQ
Question 20

LD TUQ
Question 21

tuq_15

tuq_16

tuq_17

tuq_18

tuq_19

tuq_20

tuq_21

Categorical

completing them inperson.
I received assistance
with any problems I
experienced with
Zoom®, including
help with set-up
and/or technical
difficulties.

Categorical

I felt comfortable
communicating with
the living donor
team members using
the Telehealth.

Categorical

If I made a mistake
using Telehealth
(Zoom®), I could
recover easily and
quickly.

Categorical

Telehealth met my
need to attend an
evaluation for living
kidney donation.

Categorical

Telehealth is an
acceptable way to
complete a living
donor evaluation
including education
and consults with
the living donor
team healthcare
providers.

Categorical

I would use
Telehealth again.

Categorical

Overall, I am
satisfied with my
Telehealth/virtual
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7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
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living donor
evaluation.
Additional
Comments

ld_comments

Text

Please include any
additional thoughts
or comments here.
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5. More or less agree
6. Agree
7. Strongly agree

Table 7: Data Dictionary Table (Healthcare Provider TUQ Survey)
Data Element

Data Label

Data Type

Definition/Purpose
System generated
unique identifier
Healthcare Provider
Role

Record ID

Record_IDhp

Healthcare
Provider Role

Hp_role

Alphanumeric
Categorical

HCP TUQ
Question 1

tuq_1hp

Categorical

I like using
Telehealth to
complete the
functions of my job.

HCP TUQ
Question 2

tuq_2hp

Categorical

Telehealth (Zoom®)
helps me manage
my clinic schedule
efficiently.

HCP TUQ
Question 3

tuq_3hp

Categorical

HCP TUQ
Question 4

tuq_4hp

Categorical

Telehealth is a costeffective option for
potential living
donors undergoing
an evaluation and
for completing postdonation follow-up
requirements.
Telehealth improves
patient access to
transplant and living
donation healthcare
services.

HCP TUQ
Question 5

tuq_5hp

Categorical

Zoom® is a simple
system and easy to
navigate.

Data Values & Coding
Alpha-numeric
1, Physician
2, Coordinator
3, Social Worker
4, Other
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
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HCP TUQ
Question 6

tuq_6hp

Categorical

It was easy to learn
how to set up and
use Telehealth
(Zoom®).

HCP TUQ
Question 7

tuq_7hp

Categorical

The way I am able
to interact with my
patients through
Zoom® is pleasant.

HCP TUQ
Question 8

tuq_8hp

Categorical

I like using
telehealth (Zoom®).

HCP TUQ
Question 9

tuq_9hp

Categorical

I can hear my
patients clearly
using the Telehealth
system (Zoom®).

HCP TUQ
Question 10

tuq_10hp

Categorical

I can communicate
with donors
effectively when
using the Telehealth
system (Zoom®).

HCP TUQ
Question 11

tuq_11hp

Categorical

When using
Telehealth
(Zoom®), I can
examine a donor as
well as if we met in
person.

HCP TUQ
Question 12

tuq_12hp

Categorical

Individuals
completing
Telehealth
evaluations
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4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
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understand the
education and
information
provided and can
make an informed
decision about living
donation, just the
same as if their
education/evaluation
was completed inperson.
I can do everything I
want to do during
Telehealth donor
appointments
(charting, physical
examinations, screen
sharing, playing
power point
presentations, etc.)
I find Telehealth
evaluations are
comparable to the
quality of care
delivered during inperson evaluations

HCP TUQ
Question 13

tuq_13hp

Categorical

HCP Question
14

tuq_14hp

Categorical

HCP TUQ
Question 15

tuq_15hp

Categorical

I feel I have
sufficient IT support
for Telehealth visits.

HCP TUQ
Question 16

tuq_16hp

Categorical

HCP TUQ
Question 17

tuq_17hp

Technical
difficulties
sometimes happen
during Telehealth
(Zoom®)
appointments, but
they are typically
easy to resolve and
do not prevent me
from evaluating my
patient(s).
Whenever I make a
mistake using the
Telehealth system
(Zoom®), I can

Categorical
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5. More or less agree
6. Agree
7. Strongly agree

1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
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recover easily and
quickly.
Telehealth meets my
needs when
evaluating
individuals for
living donation and
those needing postdonation follow up
care.
Telehealth is an
acceptable way to
evaluate and educate
potential living
donors.

HCP TUQ
Question 18

tuq_18hp

Categorical

HCP TUQ
Question 19

tuq_19hp

Categorical

HCP TUQ
Question 20

tuq_20hp

Categorical

I am open to the
continued use of
Telehealth (Zoom®)
for living donor
evaluations and
follow-up visits.

LD TUQ
Question 21

tuq_21hp

Categorical

Overall, I am
satisfied with using
Telehealth (Zoom®)
to evaluate living
donors.

Additional
Comments

ld_comments

Text

Please include any
additional thoughts
or comments here.
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6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree

Table 8: Data Dictionary Table (Interventional Data Collection Form/Telehealth Living
Donor Evaluations)
Data Element

Data Label

Subject
Identifer
Donor gender

Record_IDhp

Donor
Race/ethnicity

Data Type

Definition/Purpose

ldgender

Alphanumeric
Categorical

System generated
unique identifier
Self-identified
gender

ldrace

Categorical

Self-identified race

Data Values & Coding
Alpha-numeric
1, Male; 2, Female; 3,
Transgender; 4, Other; 5,
Prefer Not to Say
1, White; 2, Hispanic or
Latino; 3, Black or
African American; 4,
Native American or
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Donor Age

adage

Location of
ldlocation
Donor
(District of
Columbia,
Virginia,
Maryland,
other state,
other country)
Timeframe
LDQ_to_eval
(LDQ to Eval)

Categorical

Self-identified age
range

Categorical

Does the donor live
in the District of
Columbia, Virginia,
or Maryland?

Numeric,
Continuous

Timeframe
(Eval to
Clearance
Date)

Eval_to_clear

Numeric,
Continuous

Timeframe
(Referral to
Clearance
Date)

Ref_to_clear

Take off work
for
testing/labs

ldtakeoffwork2

PTO

ldpto

Categorical

Testing at
affiliated
NKR Center

NKR

Categorical

Plane, Train,
etc. Travel

Travel_LD

Numeric,
Continuous

Categorical

Categorical

(# of days) from
DASH questionnaire
submission to time
of scheduled virtual
evaluation
appointment
Timeframe (# of
days) from virtual
evaluation
appointment date to
date deemed eligible
for donation/cleared
for surgery
Timeframe (# of
days) from referral
to date deemed
eligible for
donation/cleared for
surgery
Did the donor take
off work to complete
labs and diagnostic
testing?
If they took off
work, are they able
to use PTO?
Did the donor/will
the donor complete
testing at affiliated
NKR center as a
Remote Donor?
Did the donor travel
by plane/train to to
complete their
evaluation testing?
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American Indian; 5,
Asian/Pacific Islander; 6,
Other.
1, 18-25; 2, 26-35; 3, 3645; 4, 46-55; 5, 56-65; 6,
66-75; 7, 76-85
1, DC; 2, Maryland; 3,
Virginia; 4, Other State;
5, Another
Country/International

Actual Numeric Value

Actual Numeric Value

Actual Numeric Value

1, Yes; 0, No
1, Yes; 0, No; 3, I did not
have to take off work/this
does not apply to me
1, Yes; 0, No

1, Yes; 0, No
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Hotel

Hotel_LD

Categorical

Total Donor
reported
estimated
Costs for Eval

Totalcost

Numeric,
Continuous

Distance to
travel to
Transplant
Center

Distance_LD

Hours to
travel to
Transplant
Center

Time_LD

Time, effort,
and/or
financial
burden

burden_1

Estimated
Costs if they
were required
to travel to
Washington
D.C.

EstimatedCosts

Hotel for
living donor
nephrectomy
surgery

ControlHotel_Sur
gery1

Categorical

Plane Travel
for living
donor
nephrectomy
surgery

Plane_Surgery

Categorical

Numeric,
Continuous

Numeric,
Continuous

Categorical

Numeric,
Continuous

Did the donor stay
in a hotel while
completing their
evaluation testing?
Donor reported
estimated costs
related to their
virtual/Telehealth
evaluation
Distance to travel to
transplant center (in
# of Miles) if donor
were to complete inperson evaluation
Time (in # hours) it
would take donor to
travel to transplant
center for in-person
evaluation
Would it be a
greater burden for
donor to travel D.C.
to complete a full
day in-person eval
compared to current
virtual evaluation
and testing
practices?
Estimated costs if
they were required
to travel to
Washington D.C. to
complete a full day
in-person living
donor evaluation?
Did the donor stay
in a hotel for their
living donor
nephrectomy
surgery?
Will the donor travel
by plane for their
living donor
nephrectomy
surgery?
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1, Yes; 0, No

Actual Numeric Value

Actual Numeric Value

Actual Numeric Value

1, Yes; 0, No

Actual Numeric Value

1, Yes; 0, No

1, Yes; 0, No
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Table 9: Data Dictionary Table (Control Group Data Collection Form/In-person Living
Donor Evaluations)
Data Element

Data Label

Subject
Identifer
Donor gender

Control_ID

Data Type

Definition/Purpose

Control_ldgender

Alphanumeric
Categorical

Excel unique
identifier
Self-identified
gender from EHR

Donor
Race/ethnicity

Control_ldrace

Categorical

Self-identified race
from EHR

Donor Age

Control_adage

Categorical

Self-identified age
range from EHR

Location of
Donor
(District of
Columbia,
Virginia, or
Maryland?)
Timeframe
(LDQ to Eval)

Control_ldlocation

Categorical

Does the donor live
in the District of
Columbia, Virginia,
or Maryland?

ControlLDQ_to_e
val

Numeric,
Continuous

(# of days) from
DASH questionnaire
submission to time
of scheduled inperson evaluation
appointment
Timeframe (# of
days) from virtual
evaluation
appointment date to
date deemed eligible
for donation/cleared
for surgery
Scheduled for
surgery/Did
individual donate
their kidney?
Did the donor take
off work to complete
labs and diagnostic
testing?
If they took off
work, are they able
to use PTO?

Timeframe
(Eval to
Clearance)

ControlEval_to_cl
ear

Numeric,
Continuous

Scheduled for
surgery

Control
Surgery_LD

Categorical

Take off work
for
testing/labs

Controlldtakeoffw
ork2

Categorical

PTO

Controlldpto

Categorical

Data Values & Coding
Alpha-numeric
1, Male; 2, Female; 3,
Transgender; 4, Other; 5,
Prefer Not to Say
1, White; 2, Hispanic or
Latino; 3, Black or
African American; 4,
Native American or
American Indian; 5,
Asian/Pacific Islander; 6,
Other.
1, 18-25; 2, 26-35; 3, 3645; 4, 46-55; 5, 56-65; 6,
66-75; 7, 76-85
1, DC; 2, Maryland; 3,
Virginia; 4, Other State;
5, Another
Country/International

Actual Numeric Value

Actual Numeric Value

1, Yes; 0, No

1, Yes; 0, No
1, Yes; 0, No; 3, I did not
have to take off work/this
does not apply to me
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Testing at
affiliated
NKR Center

ControlNKR

Plane, Train,
etc. Travel

ControlTravel_LD

Hotel

ControlHotel_LD

Categorical

Categorical

Categorical

Donor
reported Costs
for Eval

ControlTotalcost

Numeric,
Continuous

Distance to
travel to
Transplant
Center

ControlDistance_
LD

Numeric,
Continuous

Hours to
travel to
Transplant
Center

ControlTime_LD

Numeric,
Continuous

Hotel for
living donor
nephrectomy
surgery

ControlHotel_Sur
gery

Categorical

Plane Travel
for living
donor
nephrectomy
surgery

ControlPlane_Sur
gery

Categorical

Did the donor/will
the donor complete
testing at affiliated
NKR center as a
Remote Donor?
Did the donor travel
by plane/train to
complete their
evaluation testing?
Did the donor stay
in a hotel while
completing their
evaluation testing?
Donor reported costs
related to their
virtual/Telehealth
evaluation and
donation
Distance to travel to
transplant center (in
# of Miles) if donor
were to complete inperson evaluation
Time (in # hours) it
took donor to travel
to transplant center
for in-person
evaluation
Did the donor stay
in a hotel for their
living donor
nephrectomy
surgery?
Did the donor travel
by plane for their
living donor
nephrectomy
surgery?
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1, Yes; 0, No

1, Yes; 0, No

1, Yes; 0, No

Actual Numeric Value

Actual Numeric Value

Actual Numeric Value

1, Yes; 0, No

1, Yes; 0, No
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Appendix A: SWOT Analysis

Internal Origin
(Attributes of the
organization)

•
•
•
•

External Origin
(Attributes of the
organization)

Helpful to Achieving Objectives

Opportunities
• Duty to appraise additional means of
decreasing obstacles to living
donation as a reputable transplant
center
• Sustain the use of telehealth in
response to the Covid-19 pandemic to
help improve overall care, rather than
just driving more use of telehealth as
an end to itself

Strengths
Team Unity/Self-Organization
Dedicated Team Members
Expertise/ Highly recognized
Telehealth infrastructure currently in
place

Harmful to Achieving Objectives

Weaknesses
• Staff Turn-over
• Healthcare provider and
healthcare staff workload

•
•
•
•

Threats
Competition
Reluctance of patients to use
telehealth
Government Regulations
Safety
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Appendix B: Evidence Table
Article
#

1

Author
and Date

Dixon et
al., 2016

Evidence
Type

Randomized
Controlled
Trial

Sample, Sample Size,
Setting
Sample/Setting:
Adults with a 10-year
CVD risk ≥20%, as
measured by the
QRISK2 algorithm,
with at least 1
modifiable risk factor.
Participants aged
between 40 and 74 on
the date of invitation
were recruited from 42
general practices in or
near Bristol, Sheffield
and Southampton,
England. The mean
age of participants in
the trial was 67.2
years, of whom 80%
were male, and 99% of
all participants were of
white ethnicity.
Sample Size: The trial
recruited a total of 641
participants: 325 were
randomized to receive
the intervention and
316 received usual
care in the control
arm.

2

Gonzalez
Garcia et
al., 2019

Systematic
Review

The authors inspected
the references of
guidelines and
searched PubMed for
randomized controlled
trials published over
the past 10 years on
the use of telemedicine
for reducing
readmission in heart
failure.
N= 12. A total of 12
RCTs were eligible
and included in this
review. In total, 2321
patients were included
in the chosen studies,
with an average age of
73 years and
approximately 43%
female

Findings That
Help Answer
EBP Question

Costeffectiveness
measured by net
monetary benefit
at the end of 12
months of followup, calculated
from incremental
cost and
incremental
quality-adjusted
life years
(QALYs).
Productivity
impacts,
participant outof-pocket
expenditure and
the clinical
outcome were
presented in a
costconsequences
framework.

Telemedicine and
digital health
technologies hold
great promise for
improving
clinical care of
heart failure.
However,
inconsistent and
contradictory
findings from
randomized
controlled trials
have so far
discouraged
widespread
adoption of
digital health in
routine clinical
practice. This
review study was
done to
summarize the
study outcomes
of telemedicine in
the clinical care
of patients with

Observable
Measures

Participants
randomized to
usual care (inperson) reported
higher mean per
patient private
healthcare costs
than in the
intervention arm
(telehealth), but
lower out-ofpocket
expenditure than
intervention
participants.
There is evidence
to suggest that the
Healthlines
telehealth
intervention was
likely to be costeffective at a
threshold of £20
000 per QALY
(27,659.90 USD).
The outcomes of
6 RCTs supported
in general the use
of telemedicine to
reducing
readmission in
HF.
The costs and
cost-savings of
the telemedicine
intervention were
specified in 2 of
the 5 studies and
in 1 of them it
was concluded
that the costs of
the integrated
technology-based
management
were more
expensive than
usual care
although the cost
of adverse events
was significantly
lower.

Limitations

Evidence
Level,
Quality

The
recruitment
rate of the
trial was
relatively low.
This would
possibly
affect the
generalizabilit
y of the
findings,
although it is
unclear
whether low
reluctance
was due to
lack of
interest in
telehealth or
unwillingness
to participate
in research.

Level of
Evidence:
I
Quality
Rating: B

The authors
did not adopt
an
overarching
definition of
telemedicine.
None of the
studies
identified
addressed the
level of
literacy of the
participants,
that is, the
magnitude of
use or the
grade of
acceptance of
technologies
such as
computers or
smartphones.

Level of
Evidence:
II
Quality
Rating: B
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heart failure and
readmissions.

Sample: In total, 1369
participants who were
aged ≥18 years and
lived in Australia were
recruited via targeted
advertisements on
social media (ie,
Facebook and
Instagram).

3

4

Isautier et
al., 2020

Noel et
al., 2020

Nonexperimenta
l; Crosssectional
survey

Randomized
Controlled
Trial

Of the 1369
respondents who
completed the June
survey, 596 (43.5%)
reported using
telehealth services
since the start of the
pandemic.
Respondents who used
telehealth services
were slightly older,
more likely to be
female, and had higher
levels of education.

Sample Size: 451
patients were assessed
for eligibility for the
trial. 102 patients met
inclusion criteria for
study participation,
gave informed
consent, and were
enrolled in the study
prior to discharge. 45
patients were
randomized to the
TTOC group while 57
patients received the
standard of care.
Sample: the study
arms were balanced by
characteristics as there

This study aimed
to compare
participants’
perceptions of
telehealth
consults to their
perceptions of
traditional inperson visits and
investigate
whether they
experienced any
barriers to using
telehealth
services.

This is a 12month
randomized
controlled trial,
evaluating the use
of telehealth
(remote patient
monitoring and
video visits)
versus standard
transitions of care
with the primary
outcomes of
hospital
readmission and
emergency
department
utilization and
secondary

The majority of
respondents
(n=369, 61.9%)
stated that their
telehealth
experience was
“just as good as”
or “better than”
their traditional
in-person medical
visit experience.
On average,
respondents
perceived
telehealth as
moderately useful
to very useful for
medical
appointments
after the COVID19 pandemic ends
(mean 3.67, SD
1.1).
Respondents
perceived that
telehealth would
be moderately
useful to very
useful for medical
appointments
after the COVID19 pandemic.
This suggests that
telehealth may be
a viable longterm option for
health care
delivery.
Compared with
the standard of
care, Telehealth
patients were
more likely to
have medicine
reconciliation
(p = 0.013) and
were 7 times
more likely to
adhere to
medication than
the control group
(p = 0.03).
Telehealth
patients exhibited
enthusiasm
(p = 0.0001), and
confidence that

While the
study sample
was large and
diverse, it was
not
statistically
representative
of the
Australian
population,
consisting of
a higher
proportion of
females,
higher level
of education,
and
potentially
higher levels
of digital
literacy than
the general
population.

Level of
Evidence:
III
Quality
Rating: B

Participants
might not be
representative
of general
population:
Patients were
excluded if
they had
physical
limitations
prohibiting
the use of the
telehealth
equipment,
were
uninsured
(who received
referrals
elsewhere for

Level of
Evidence:
I
Quality
Rating: B

EVALUATING TELEHEALTH FOR LIVING DONORS
were no statistically
significant differences
between the groups in
regard to
demographics
including gender, race
and education (Table
1). The average age at
enrollment was
65 years.

outcomes of
access to care,
medication
management and
adherence and
patient
engagement.

Setting: This study
was performed by the
Family and Internal
Medicine Departments
at Stony Brook
Medicine, which is a
603-bed teaching
institution on the
northern part of Long
Island, New York

5

Nomura
et al.,
2019

Randomized
Controlled
Trial

Sample Size/Sample:
The study randomized
115 participants with
nicotine dependence:
58 were allocated to
the telemedicine
(internet-based video
counseling) arm and
57, to the control
(standard face-to-face
clinical visit) arm.
Mean age 55; 81%
male
Setting: Multicenter
trial in Japan

This study aimed
to evaluate the
efficacy and
feasibility of a
telehealth
smoking
cessation support
program
compared with
the standard faceto-face clinical
visit program
among patients
with nicotine
dependence.

77
Telehealth could
improve their
healthcare
(p = 0.0001).
Telehealth
showed no
statistical
significance on
emergency
department
utilization
(p = 0.691) nor
for readmissions
(p = 0.31). 100%
of Telehealth
patients found the
intervention to be
valuable, 98% if
given the
opportunity,
reported they
would continue
using telehealth
to manage their
healthcare needs,
and 94% reported
that the remote
patient
monitoring
technology was
useful.
The application
of telemedicine
using internetbased video
counseling as a
smoking
cessation
program had a
similar
“continuous
abstinence rate”
from weeks 9 to
12 as that of the
standard face-toface clinical visit
program. The
efficacy of the
telemedicinebased smoking
cessation
program was not
inferior to that of
the standard
visit–based
smoking
cessation
program.

follow up
care), if
involved in
another
research
study, were
pregnant or
actively
trying to
conceive, or if
admitted for a
primary
psychiatric
diagnosis.

Concluding
the efficacy of
telemedicine
in a 3-months
trial could be
difficult.
Further trials
lasting longer
than 3 months
might be
needed to
confirm the
long-term
efficacy
telemedicine.

Level of
Evidence:
I
Quality
Rating: B
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Setting: Eleven CVS
minute clinics in
California and Texas
Sample Size: 1734
completed a post
telehealth survey

6

Polinski
et al.,
2016

Nonexperimenta
l; Crosssectional
survey

Sample: Patients who
were 18 years of age
or older; 70 % were
women. The study
sample was compared
with the CVS
MinuteClinic general
adult population and
the U.S. adult
population 18 years
and older.

Sample Size: Enrolled
participants were
randomized to virtual
(n = 61) or in-person
(n = 60) educational
interventions.

7

Press et
al., 2020

Randomized
Controlled
Trial

Sample: Among 118
participants (59 in
each group), most
were black (114
[97%]) and female (76
[64%]), with a mean
(SD) age of 54.5
(13.0) years.
Hospitalized adult
patients aged 18 years
or older with
physician-diagnosed
asthma or COPD were
eligible.
Setting: Participants
were recruited from an
urban academic

Patients rated
their satisfaction,
quality of care,
convenience, and
overall
understanding of
their telehealth
appointment.
Patients ranked
telehealth visits
compared to
traditional ones:
better (defined as
preferring
telehealth), just as
good (defined as
liking telehealth),
or worse.

To assess whether
the virtual teachto-goal
intervention is
noninferior to an
in-person teachto-goal
intervention.
A noninferiority
design was
chosen because
the objective was
to assess whether
virtual education
is as effective but
not more
effective than inperson teaching
for initial
education.
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Between 94 and
99 % reported
being “very
satisfied” with all
telehealth
attributes. Onethird preferred a
telehealth visit to
a traditional inperson visit. An
additional 57 %
liked telehealth.
Predictors of
liking telehealth
were female
gender
(OR = 1.68, 1.04–
2.72) and being
very satisfied
with their overall
understanding of
telehealth
(OR = 2.76, 1.84–
4.15), quality of
care received
(OR = 2.34, 1.42–
3.87), and
telehealth’s
convenience
(OR = 2.87, 1.09–
7.94)

Correct technique
increased
similarly before
vs after education
in virtual (67%;
range, 2%-69%)
and in-person
(66%; range, 17%
to 83%) groups,
although the
difference after
intervention
exceeded the
noninferiority
limit (–14%; 95%
CI lower bound, –
26%). When
adjusting for
baseline inhaler
technique, the
difference was
equivalent to the
noninferiority
limit (–10%; 95%

The survey
instrument
was created
by the pilot
program
evaluation
team and was
not tested for
reliability or
validity prior
to use.
Data on the
number of
patients who
were invited
to take the
survey and
who refused
were not
available, and
the pilot
program team
could not
assess a
precise survey
response rate
or the
comparability
of survey
responders
and nonresponders
regarding
their
telehealth
experiences.
The study
population
primarily
comprised
urban,
underserved,
black patients
and the
intervention
was
developed
using direct
feedback
from this
population.
Therefore,
generalizabilit
y to clinical
and home
settings
across diverse
populations
and
geographies
needs testing

Level of
Evidence:
III
Quality
Rating: B

Level of
Evidence:
I
Quality
Rating: B
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hospital and were
similar to participants
in previous studies
evaluating efficacy of
interventions tested in
this study

Setting: Participants
were recruited from 43
general practices in
three areas of England.

8

Salisbury
et al.,
2016

Randomized
Controlled
Trial

Sample: To be
eligible, participants
needed to have access
to the internet and
email, a Patient Health
Questionnaire 9 (PHQ9) score of at least 10,
a confirmed diagnosis
of depression, and
aged 18 years or older.
Sample size: 609
participants were
randomly assigned,
with 307 assigned to
intervention plus usual
care (telehealth) and
302 assigned to usual
care alone (in-person
treatment). A total of
516 (85%) participants
were retained until the
final 12-month followup assessment.

79
CI lower bound, –
22%).
The findings
suggest that
patient-directed
virtual education
similarly
improved the
percentage of
participants with
correct technique
compared with
in-person
education.

Outcomes
measured were
quality of life
(EQ-5D-5L);
satisfaction with
treatment
received and with
amount of
support received
(patient
satisfaction);
perceived access
to care; selfmanagement
skills and selfefficacy (HeiQ);
use of telehealth
interventions; and
perceptions of
care coordination
(Haggerty).

Compared with
participants who
received usual
care alone (inperson),
participants who
received the
intervention
(telehealth)
reported reduced
anxiety, improved
access to health
support and
advice, greater
satisfaction with
the treatment and
the amount of
help they
received, and
improvements in
self-management
attitudes and
skills.

in future
head-to-head
comparisons.

Only a small
proportion of
those patients
sent
information
about the trial
expressed
interest in
participating.

Level of
Evidence:
I
Quality
Rating: B
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Setting: Patients were
recruited through five
Madrid hospitals

9

Soriano et
al., 2018

Randomized
Controlled
Trial

Sample: Inclusion
criteria for study
subjects were: Aged
50–90 years old with a
diagnosis of COPD.
Participants had a
mean ± SD age of
71 ± 8 years and 80%
were men, and all
demographic and
clinical characteristics
were evenly
distributed by group
including education
level.
Sample Size: Overall,
237 COPD patients
were screened, and
229 (96.6%) were
randomized to
telehealth (n = 115) or
routine in-person
practice (n = 114), and
169 completed the full
follow-up period

Principal
objective was to
estimate the
effectiveness of a
Telehealth in
managing
patients with
severe-very
severe COPD
when compared
to Routine
Clinical Practice
(RCP).
Secondary
objectives
included
estimating the
efficiency
(cost/effectivenes
s, cost/utility) of
telehealth in
managing severevery severe
COPD patients
compared with
routine in-person
practice, and to
evaluate patient
and clinician
satisfaction with
the telehealth
strategy.

80
Participants
overall level of
satisfaction was
scored at
8.6 ± 1.07 points
out of a
maximum 10
points. Without
exception, all
participants
(100%) would
recommend the
tele monitoring
system to a
family member or
a friend, should
they need it.
Additionally,
physicians also
responded to a
questionnaire, a
large majority
agreed or strongly
agreed with
positive
statements
regarding the
telehealth. 93.3%
of physicians
would intend to
use tele
monitoring when
necessary to
provide health
care to their
patients, and
60.0% agreed to
routinely use tele
monitoring with
their patients.

There was
reduced
formal
coordination
with Primary
Care; Likely
there was a
learning curve
with
telehealth
evident in
patients and
their doctors
during the
year.

Level of
Evidence:
I
Quality
Rating: B
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Setting: VA-based
subspecialty
Parkinson’s Disease
clinic.
Sample/Sample size:
Eighty-six men (50 in
the satellite clinic arm
and 36 in the home
telehealth arm) were
recruited.

10

Wilkinson
et al.,
2016

Randomized
Controlled
Trial)

There were no
significant
demographic
differences at baseline
between control and
intervention
individuals in either
arm.
At the conclusion of
the study, 30
individuals had
dropped out: 11 had
died and 19 withdrew.
Reasons for
withdrawal in the
telehealth groups
related to technical
issues, relocation of
clinical care, change in
frequency of visits to
annually, and
preference for inperson care.

Focused on
patient
satisfaction as
the primary
endpoint, as
well as clinical
outcomes,
patient travel
burden, and
health care
utilization,
using clinical
video telehealth
vs usual inperson care.

81
Study participants
completed a
Patient
Assessment of
Communication
of Telehealth
(PACT) 6
question
questionnaire.
Results showed:
 There were no
significant
differences in
overall
(aggregate)
patient
satisfaction
(telehealth vs.
in-person care)
 Significantly
higher
satisfaction for
telehealth
interventions
compared with
usual in-person
treatment.
 For
convenience
related to
distance to
travel,
satisfaction was
significantly
higher in
telehealth
intervention
groups.
 Telehealth
patients also
reported equal
or improved
overall
communication,
addressing of
clinical
concerns, and
overall quality
of visit
compared with
in-person visits.
 Travel burden
was decreased
for home
telehealth
participants
with a savings
of 58.2 miles
per visit.

The small
sample size
may have
decreased
power to
detect more
betweengroup
differences,
particularly in
the home
telehealth arm
because
enrollment
did not reach
the goal of 50
participants.
Recall bias
may have
affected
patient
questionnaire
responses.
Thus,
although the
evidence is
encouraging,
larger longterm studies
will be
needed to
guide
program
development
and growth,
with emphasis
on costeffectiveness,
quality, and
utilization.

Level of
Evidence:
I
Quality
Rating: B
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Appendix C: The Iowa Model Revised: EBP to Promote Excellence in Health Care

(Iowa Model Collaborative, 2017)

Used/reprinted with permission from the University of Iowa Hospitals and Clinics, copyright 2015. For
permission to use or reproduce, please contact the University of Iowa Hospitals and Clinics at 319-384-9098.
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Appendix D: Telehealth Usability Questionnaire (TUQ) for Living Donor and Health Care
Professionals

Telehealth Usability Questionnaire TUQ for Living Donors
Question

1. What is your gender?

2. What is your race/ethnicity?
3. What is your age?
4. Telehealth improves my access to
Living Kidney Donation services
(including virtual evaluations and
virtual post-donation follow-up
appointments)
5. Telehealth saves me time traveling.

6. Telehealth is a cost-saving option to
complete my living donor evaluation.

7. I am more likely to attend, and not
reschedule or miss, a Telehealth
appointment compared to an in-person
appointment.

8. It was simple to use the Telehealth
system (Zoom®) for my living donor
evaluation.

(*Adapted for use)

Answers

1, Male; 2, Female; 3, Transgender; 4, Other; 5, Prefer Not to
Say
1, White; 2, Hispanic or Latino; 3, Black or African
American; 4, Native American or American Indian; 5,
Asian/Pacific Islander; 6, Other.
1, 18-25; 2, 26-35; 3, 36-45; 4, 46-55; 5, 56-65; 6, 66-75; 7,
76-85
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
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9. It was easy to learn how to use Zoom®

10. The way I was able to interact virtually
with the living donor team through
Telehealth (Zoom®) was pleasant,

11. I like using Telehealth (Zoom®),

12. I could hear the living donor team
members clearly using Telehealth
(Zoom®).

13. I felt I was able to express myself
effectively to the healthcare providers
and living donor team members when
being evaluated virtually/through
Telehealth.
14. I was easily able to ask questions and
talk to the living donor team members
including the doctors, social worker,
and my coordinator during my
virtual/Telehealth evaluation.
15. Using Telehealth, I could see and
understand the living donor education
PowerPoint presentation as well as if it
were presented in-person.

1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
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16. I was able to do everything I wanted to
do for my Telehealth appointment.

17.

18.

19.

20.

21.

22.

1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
I think completing the living donor
1: Strongly disagree
education and consults through
2: Disagree
Telehealth were the same as if I were
3: More or less disagree
completing them in-person.
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
I received assistance with any problems 1: Strongly disagree
I experienced with Zoom®, including
2: Disagree
help with set-up and/or technical
3: More or less disagree
difficulties.
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
I felt comfortable communicating with 1: Strongly disagree
the living donor team members using
2: Disagree
the Telehealth.
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
If I made a mistake using Telehealth
1: Strongly disagree
(Zoom®), I could recover easily and
2: Disagree
quickly.
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
Telehealth met my need to attend an
1: Strongly disagree
evaluation for living kidney donation.
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
Telehealth is an acceptable way to
1: Strongly disagree
complete a living donor evaluation
2: Disagree
including education and consults with
3: More or less disagree
the living donor team healthcare
4: Undecided
providers.
5. More or less agree
6. Agree
7. Strongly agree
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23. I would use Telehealth again.

24. Overall, I am satisfied with my
Telehealth/virtual living donor
evaluation.

25. Please include any additional thoughts
or comments here.
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1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
Open ended answer/ Comment

Telehealth Usability Questionnaire for Healthcare Providers
Question

(*Adapted for use)

What is your role on the living donor team?
I like using Telehealth to complete the
functions of my job.

Telehealth (Zoom®) helps me manage my
clinic schedule efficiently.

1. Telehealth is a cost-effective option for
potential living donors undergoing an
evaluation and for completing postdonation follow-up requirements.

Telehealth improves patient access to transplant
and living donation healthcare services.

Answer Options

1, Physician 2, Coordinator 3, Social Worker 4, Other
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree

EVALUATING TELEHEALTH FOR LIVING DONORS

Zoom® is a simple system and easy to
navigate.

It was easy to learn how to set up and use
Telehealth (Zoom®).

The way I am able to interact with my patients
through Zoom® is pleasant.

2. I like using telehealth (Zoom®).

3. I can hear my patients clearly using the
Telehealth system (Zoom®).

4. I can communicate with donors effectively
when using the Telehealth system
(Zoom®).

5. When using Telehealth (Zoom®), I can
examine a donor as well as if we met in
person.

6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
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7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
I find Telehealth evaluations are
1: Strongly disagree
comparable to the quality of care delivered
2: Disagree
during in-person evaluations
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
I feel I have sufficient IT support for
1: Strongly disagree
Telehealth visits.
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
Technical difficulties sometimes happen
1: Strongly disagree
during Telehealth (Zoom®) appointments,
2: Disagree
but they are typically easy to resolve and do 3: More or less disagree
not prevent me from evaluating my
4: Undecided
patient(s).
5. More or less agree
6. Agree
7. Strongly agree
Whenever I make a mistake using the
1: Strongly disagree
Telehealth system (Zoom®), I can recover
2: Disagree
easily and quickly.
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
Telehealth meets my needs when evaluating 1: Strongly disagree
individuals for living donation and those
2: Disagree
needing post-donation follow up care.
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree

6. Individuals completing Telehealth
evaluations understand the education and
information provided and can make an
informed decision about living donation,
just the same as if their
education/evaluation was completed inperson.
7. I can do everything I want to do during
Telehealth donor appointments (charting,
physical examinations, screen sharing,
playing power point presentations, etc.)

8.

9.

10.

11.

12.
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13. Telehealth is an acceptable way to evaluate
and educate potential living donors.

14. I am open to the continued use of
Telehealth (Zoom®) for living donor
evaluations and follow-up visits.

15. Overall, I am satisfied with using
Telehealth (Zoom®) to evaluate living
donors.

1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
1: Strongly disagree
2: Disagree
3: More or less disagree
4: Undecided
5. More or less agree
6. Agree
7. Strongly agree
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Appendix E: Gantt Chart Outlining Project Timeline
Tasks
Current State
Assessment
Assembling a
project team
Share evidencebased literature
to leadership
and stakeholders
Project Proposal
Approval
Secure Internal
Review Board
and Clinical
Director
Approval
Project
Implementation
Perform data
collection and
analysis
Share feedback
and data
collection with
leadership and
stakeholders
Make
recommendation
s to modify and
improve current
practice
Project
completion and
submission

Apr
2021

May
2021

Jun
2021

Jul
2021

Aug
2021

Sep
2021

Oct
2021

Nov
2021

Dec
2021

Jan
2022

Feb
2022

Mar
2022

Apr
2022

May
2022
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Appendix F: Logic Model
Problem Statement: Telemedicine has allowed our transplant center to connect safely with our donors
during their most vulnerable time and ensured that contact with them was uninterrupted during the COVID19 pandemic. It became evident that in-person evaluation and follow-up process was cost effective for
donors. However, prospective evaluation was needed to determine whether reliance on telehealth for
communication with donors affected quality of care.
Goal: To evaluate the impact of using telehealth as the primary means of communicating with living donors
during evaluations (and follow-up appointments) and its effect on quality of care versus in-person
evaluations.
Inputs
Outputs
Outcomes
Staff Time
Activities
Participation
Short-Term
Intermediate
Long-Term
Telehealth
Infrastructure
(Zoom®)

Conduct
Living Donor
Evaluations

# of Living
Donors
participating in
Evaluations

Data collection
and analysis
platforms:
REDCap®,
OTTR, NKR
DASH, and
Medconnect EMR

Collect Data
and Analysis

# of Healthcare
providers

Create and
Distribute
Electronic
Surveys

# of Days
Between
Scheduled
Evaluation Date
and Clearance
Date
# of Living
Donors Cleared
for Surgery
# of TUQ
surveys
completed
# of days
between NKR
DASH
questionnaire
submission and
scheduled
evaluation date
Estimated Donor
Out-of-Pocket
Costs of Travel,
Lost Wages, etc.

Outlook/Email
access to send
survey to
donors/healthcare
providers

NKR DASH
questionnaires

Assumptions

Living donors will
Report an Overall
Positive
Experience with
Telehealth
Communications

Telehealth
Evaluations will
Improve Access to
Living Donation
Services

Increased
Community
Awareness
Regarding the
Benefits of
Telehealth

Telehealth
Evaluations will
Improve the
Financial Impact on
Living Donors
Telehealth
Evaluations
will Provide
Overall High
Quality of
Care for
Living Donors
and

Healthcare
Providers will
Report an Overall
Positive
Experience with
Telehealth
Communications
Telehealth will
Maintain
Evaluations
Effectiveness

External Factors
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 Barriers to living donation are due to
anticipated cost of travel and time off work
 Stakeholders will be engaged
 Staff/identified team members will be
receptive and enthused to participate in the
program
 There will be adequate time allotted to
complete and evaluate the project
 Our transplant center will be financially
stable to initiate and continue with the
study
 Implementation of the study will produce
long term benefits for our
organization/living donors.







Reluctance of patients to use telehealth
Management practices
Work unit climate including staff turn over
Tasks and individual skills
Individual needs and values
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Appendix G: Living Donor TUQ Results and Data Analysis
Telehealth Usability Questionnaire (TUQ) for Living Donors
(*Adapted for use) (N =64)
Answers are based on a 7-point Likert scale: (1) Strongly disagree, (2) Disagree, (3) More or less disagree, (4)
Undecided, (5) More or less agree, (6) Agree, (7) Strongly agree
Item

1.
2.
3.
4.

5.
6.
7.
8.
9.

Median
Score
6.33 (0.04)
6.34

Range 1-7

6.44

(5.0-7.0)

Telehealth is a cost-saving option to complete my living
donor evaluation.
I am more likely to attend, and not reschedule or miss, a
Telehealth appointment compared to an in-person
appointment.

6.27

(4.0-7.0)

6.28

(5.0-7.0)

Ease of Use Scale (Items 5-8)
It was simple to use the Telehealth system (Zoom®) for
my living donor evaluation.
It was easy to learn how to use Zoom®
The way I was able to interact virtually with the living
donor team through Telehealth (Zoom®) was pleasant,
I like using Telehealth (Zoom®),

6.21 (0.29)
6.25

(6.0-7.0)
(5.0-7.0)

5.78
6.42

(2.0-7.0)
(5.0-7.0)

6.38

(5.0-7.0)

Effectiveness (Items 9-13)
I could hear the living donor team members clearly using
Telehealth (Zoom®).

6.35 (0.08)
6.41

(4.0-7.0)
(5.0-7.0)

Usefulness Scale (Items 1-4)
Telehealth improves my access to Living Kidney Donation
services (including virtual evaluations and virtual postdonation follow-up appointments)
Telehealth saves me time traveling.

(4.0-7.0)
(4.0-7.0)

10.

I felt I was able to express myself effectively to the
healthcare providers and living donor team members when
being evaluated virtually/through Telehealth.

6.38

(4.0-7.0)

11.

I was easily able to ask questions and talk to the living
donor team members including the doctors, social worker,
and my coordinator during my virtual/Telehealth
evaluation.
Using Telehealth, I could see and understand the living
donor education PowerPoint presentation as well as if it
were presented in-person.

6.27

(5.0-7.0)

6.44

(5.0-7.0)

I was able to do everything I wanted to do for my
Telehealth appointment.

6.28

(5.0-7.0)

Reliability (Items 14-17)
I think completing the living donor education and consults
through Telehealth were the same as if I were completing
them in-person.

6.17 (0.16)
6.38

(5.0-7.0)
(3.0-7.0)

I received assistance with any problems I experienced with
Zoom®, including help with set-up and/or technical
difficulties.

5.98

(3.0-7.0)

12.
13.

14.
15.
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16.

I felt comfortable communicating with the living donor
team members using the Telehealth.

6.13

(4.0-7.0)

17.

If I made a mistake using Telehealth (Zoom®), I could
recover easily and quickly.

6.20

(4.0-7.0)

6.45 (0.04)
6.50

(5.0-7.0)
(5.0-7.0)

6.42

(5.0-7.0)

6.41
6.45

(5.0-7.0)
(5.0-7.0)

18.
19.
20.
21.

Satisfaction (Items 18-21)
Telehealth met my need to attend an evaluation for living
kidney donation.
Telehealth is an acceptable way to complete a living donor
evaluation including education and consults with the living
donor team healthcare providers.
I would use Telehealth again.
Overall, I am satisfied with my Telehealth/virtual living
donor evaluation.

Usefulness Scale (Items 1-4)
100%
90%
80%
70%

48%

34%

39%

59%

50%

53%

60%
50%
40%
30%

39%

20%
10%

11%

38%
9%

5%

11%

Telehealth improves my
access to Living Kidney
Donation services
(including virtual
evaluations and virtual
post-donation follow-up
appointments)

Telehealth saves me
time traveling.

Telehealth is a costsaving option to
complete my living
donor evaluation.

I am more likely to
attend, and not
reschedule or miss, a
Telehealth appointment
compared to an inperson appointment.

Strongly Agree

48%

53%

34%

39%

Agree

39%

38%

59%

50%

More or Less Agree

11%

9%

5%

11%

Undecided

2%

0%

2%

0%

More or Less Disagree

0%

0%

0%

0%

Disagree

0%

0%

0%

0%

Strongly Disagree

0%

0%

0%

0%

0%
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Ease of Use Scale (Items 5-8)
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

27%

34%

55%

52%

33%

34%

9%

13%

14%

It was simple to use the
Telehealth system
(Zoom®) for my living
donor evaluation.

It was easy to learn how
to use Zoom®

The way I was able to
interact virtually with
the living donor team
through Telehealth
(Zoom®) was pleasant,

I like using Telehealth
(Zoom®),

Strongly Agree

34%

27%

55%

52%

Agree

56%

48%

33%

34%

More or Less Agree

9%

9%

13%

14%

Undecided

0%

9%

0%

0%

More or Less Disagree

0%

5%

0%

0%

Disagree

0%

2%

0%

0%

Strongly Disagree

0%

0%

0%

0%

48%
56%
9%

Effectiveness Scale (Items 9-13)
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

52%

48%

38%

42%

11%

I could hear the
living donor team
members clearly
using Telehealth
(Zoom®).

39%

48%

13%
I was easily able to
I felt I was able to
ask questions and
express myself
talk to the living
effectively to the
donor team
healthcare
members including
providers and living
the doctors, social
donor team
worker, and my
members when
coordinator during
being evaluated
my
virtually/through
virtual/Telehealth
Telehealth.
evaluation.
8%

53%

38%

38%

53%

9%

9%

Using Telehealth, I
could see and
understand the
living donor
education
PowerPoint
presentation as
well as if it were
presented inperson.

I was able to do
everything I wanted
to do for my
Telehealth
appointment.

Strongly Agree

52%

48%

39%

53%

38%

Agree

38%

42%

48%

38%

53%

More or Less Agree

11%

8%

13%

9%

9%

Undecided

0%

2%

0%

0%

0%

More or Less Disagree

0%

0%

0%

0%

0%

Disagree

0%

0%

0%

0%

0%

Strongly Disagree

0%

0%

0%

0%

0%
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Reliability Scale (Items 14-17)
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

48%

33%

42%

34%

48%

44%
17%
6%
I think completing the
living donor education
and consults through
Telehealth were the
same as if I were
completing them inperson.

42%

41%

13%

13%

I received assistance
with any problems I
experienced with
Zoom®, including help
with set-up and/or
technical difficulties.

I felt comfortable
communicating with the
living donor team
members using the
Telehealth.

If I made a mistake using
Telehealth (Zoom®), I
could recover easily and
quickly.
42%

Strongly Agree

48%

33%

34%

Agree

44%

42%

48%

41%

More or Less Agree

6%

17%

13%

13%

Undecided

0%

6%

5%

5%

More or Less Disagree

2%

2%

0%

0%

Disagree

0%

0%

0%

0%

Strongly Disagree

0%

0%

0%

0%

Satisfaction Scale (Items 18-21)
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

56%

38%
6%
Telehealth met my need
to attend an evaluation
for living kidney
donation.

50%

50%

52%

42%

41%

42%

8%
Telehealth is an
acceptable way to
complete a living donor
evaluation including
education and consults
with the living donor
team healthcare
providers.

9%

6%

I would use Telehealth
again.

Overall, I am satisfied
with my
Telehealth/virtual living
donor evaluation.

Strongly Agree

56%

50%

50%

52%

Agree

38%

42%

41%

42%

More or Less Agree

6%

8%

9%

6%

Undecided

0%

0%

0%

0%

More or Less Disagree

0%

0%

0%

0%

Disagree

0%

0%

0%

0%

Strongly Disagree

0%

0%

0%

0%
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Appendix H: Healthcare Provider TUQ Results and Data Analysis
Telehealth Usability Questionnaire (TUQ) for Healthcare Providers
(*Adapted for use) (N =11)
Answers are based on a 7-point Likert scale: (1) Strongly disagree, (2) Disagree, (3) More or less disagree, (4)
Undecided, (5) More or less agree, (6) Agree, (7) Strongly agree
Item

Mean Score
(SD)

Range 1-7

Usefulness Scale (Items 1-4)

6.68 (0.05)

(6.0-7.0)

1.

I like using Telehealth to complete the functions of my
job.

6.73

(6.0-7.0)

2.

Telehealth (Zoom®) helps me manage my clinic schedule
efficiently.

6.82

(6.0-7.0)

3.

Telehealth is a cost-effective option for potential living
donors undergoing an evaluation and for completing postdonation follow-up requirements.

6.73

(6.0-7.0)

4.

Telehealth improves patient access to transplant and
living donation healthcare services.

6.82

(6.0-7.0)

6.62 (0.16)

(6.0-7.0)

Ease of Use Scale (Items 5-8)
5.

Zoom® is a simple system and easy to navigate.

6.45

(6.0-7.0)

6.

It was easy to learn how to set up and use Telehealth
(Zoom®).

6.55

(6.0-7.0)

7.

The way I am able to interact with my patients through
Zoom® is pleasant.

6.64

(6.0-7.0)

8.

I like using telehealth (Zoom®).

6.82

(6.0-7.0)

6.38 (0.50)

(3.0-7.0)

Effectiveness (Items 9-13)
9.

I can hear my patients clearly using the Telehealth system
(Zoom®).

6.73

(6.0-7.0)

10.

I can communicate with donors effectively when using
the Telehealth system (Zoom®).

6.64

(6.0-7.0)

11.

When using Telehealth (Zoom®), I can examine a donor
as well as if we met in person.

5.55

(3.0-7.0)

12.

Individuals completing Telehealth evaluations understand
the education and information provided and can make an
informed decision about living donation, just the same as
if their education/evaluation was completed in-person.

6.73

(6.0-7.0)

13.

I can do everything I want to do during Telehealth donor
appointments (charting, physical examinations, screen
sharing, playing power point presentations, etc.)

6.27

(5.0-7.0)

6.38 (0.04)

(5.0-7.0)

Reliability (Items 14-17)
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14.

I find Telehealth evaluations are comparable to the
quality of care delivered during in-person evaluations

6.36

(5.0-7.0)

15.

I feel I have sufficient IT support for Telehealth visits.

6.45

(6.0-7.0)

16.

Technical difficulties sometimes happen during
Telehealth (Zoom®) appointments, but they are typically
easy to resolve and do not prevent me from evaluating
my patient(s).

6.36

(6.0-7.0)

17.

Whenever I make a mistake using the Telehealth system
(Zoom®), I can recover easily and quickly.

6.36

(6.0-7.0)

6.66 (0.14)

(6.0-7.0)

Satisfaction (Items 18-21)
18.

Telehealth meets my needs when evaluating individuals
for living donation and those needing post-donation
follow up care.

6.55

(6.0-7.0)

19.

Telehealth is an acceptable way to evaluate and educate
potential living donors.

6.55

(6.0-7.0)

20.

I am open to the continued use of Telehealth (Zoom®)
for living donor evaluations and follow-up visits.

6.73

(6.0-7.0)

21.

Overall, I am satisfied with using Telehealth (Zoom®) to
evaluate living donors.

6.82

(6.0-7.0)

Usefulness Scale (Items 1-4)
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

73%

82%

73%

82%

27%

18%

27%

18%

I like using
Telehealth to
complete the
functions of my job.

Telehealth (Zoom®)
helps me manage my
clinic schedule
efficiently.

Telehealth is a costeffective option for
potential living
donors undergoing
an evaluation and
for completing postdonation follow-up
requirements.

Telehealth improves
patient access to
transplant and living
donation healthcare
services.

Strongly Agree

73%

82%

73%

82%

Agree

27%

18%

27%

18%

More or Less Agree

0%

0%

0%

0%

Undecided

0%

0%

0%

0%

More or Less Disagree

0%

0%

0%

0%

Disagree

0%

0%

0%

0%

Strongly Disagree

0%

0%

0%

0%
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Ease of Use Scale (Items 5-8)
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

45%

55%

55%

64%

45%

82%

36%

18%

Zoom® is a simple
system and easy to
navigate.

It was easy to learn
how to set up and
use Telehealth
(Zoom®).

Strongly Agree

45%

55%

64%

82%

Agree

55%

45%

36%

18%

More or Less Agree

0%

0%

0%

0%

Undecided

0%

0%

0%

0%

More or Less Disagree

0%

0%

0%

0%

Disagree

0%

0%

0%

0%

Strongly Disagree

0%

0%

0%

0%

100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

The way I am able to
interact with my
I like using telehealth
patients through
(Zoom®).
Zoom® is pleasant.

Effectiveness Scale (Items 9-13)
73%

64%

27%

36%

36%
27%

73%

45%
36%

27%

Individuals completing
Telehealth evaluations
understand the
I can do everything I
education and
want to do during
I can communicate
When using
information provided
Telehealth donor
I can hear my patients
with donors
Telehealth (Zoom®), I
and can make an
appointments
clearly using the
effectively when using can examine a donor
informed decision
(charting, physical
Telehealth system
the Telehealth system as well as if we met in about living donation, examinations, screen
(Zoom®).
(Zoom®).
person.
just the same as if
sharing, playing power
their
point presentations,
education/evaluation
etc.)
was completed inperson.

Strongly Agree
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Reliability Scale (Items 14-17)
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

45%

45%

45%

55%

36%

36%

64%

64%

Whenever I make a
mistake using the
Telehealth system
(Zoom®), I can recover
easily and quickly.

I find Telehealth
evaluations are
comparable to the
quality of care delivered
during in-person
evaluations.

I feel I have sufficient IT
support for Telehealth
visits.

Technical difficulties
sometimes happen
during Telehealth
(Zoom®) appointments,
but they are typically
easy to resolve and do
not prevent me from
evaluating my patient(s).
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Satisfaction Scale (Items 18-21)
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Telehealth meets my
needs when evaluating
individuals for living
donation and those
needing post-donation
follow up care.

Telehealth is an
acceptable way to
evaluate and educate
potential living donors.

I am open to the
continued use of
Telehealth (Zoom®) for
living donor evaluations
and follow-up visits.

Overall, I am satisfied
with using Telehealth
(Zoom®) to evaluate
living donors.
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